WO2022089392A1 - 抗tigit抗体、其药物组合物及用途 - Google Patents

抗tigit抗体、其药物组合物及用途 Download PDF

Info

Publication number
WO2022089392A1
WO2022089392A1 PCT/CN2021/126277 CN2021126277W WO2022089392A1 WO 2022089392 A1 WO2022089392 A1 WO 2022089392A1 CN 2021126277 W CN2021126277 W CN 2021126277W WO 2022089392 A1 WO2022089392 A1 WO 2022089392A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
tigit
cancer
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2021/126277
Other languages
English (en)
French (fr)
Inventor
李百勇
夏瑜
王忠民
张鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akeso Pharmaceuticals Inc
Original Assignee
Akeso Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3194641A priority Critical patent/CA3194641A1/en
Priority to JP2023525079A priority patent/JP7780521B2/ja
Priority to US18/250,440 priority patent/US20240002504A1/en
Priority to KR1020237016952A priority patent/KR20230098221A/ko
Priority to EP21885119.4A priority patent/EP4253414A4/en
Priority to AU2021372706A priority patent/AU2021372706A1/en
Application filed by Akeso Biopharma Inc filed Critical Akeso Biopharma Inc
Priority to IL302411A priority patent/IL302411A/en
Priority to MX2023004808A priority patent/MX2023004808A/es
Publication of WO2022089392A1 publication Critical patent/WO2022089392A1/zh
Anticipated expiration legal-status Critical
Priority to ZA2023/05217A priority patent/ZA202305217B/en
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the invention belongs to the field of medicine, and relates to an anti-TIGIT antibody, its pharmaceutical composition and use. Specifically, the present invention relates to an anti-TIGIT monoclonal antibody.
  • TIGIT T cell Ig and ITIM domain, also known as WUCAM, Vstm3, VSIG9 is a member of the poliovirus receptor (PVR)/Nectin family.
  • TIGIT consists of an extracellular immunoglobulin variable (IgV) domain, a type I transmembrane domain, and a classical immunoreceptor tyrosine inhibitory motif (ITIM) and immunoglobulin tyrosine tail (ITT) motifs of intracellular domains.
  • TIGIT is highly expressed in lymphocytes, especially in effector and regulatory CD4+ T cells, follicular helper CD4+ T cells and effector CD8+ T cells, and natural killer (NK) cells (Yu X, Harden K, Gonzalez L C, et al. al.
  • NK natural killer cells
  • CD155 also known as PVR, Necl5 or Tage4
  • CD112 also known as PVRL2/nectin 2
  • CD113 also known as PVRL3
  • CD155 is a high-affinity ligand of TIGIT.
  • TIGIT-binding ligands CD155 and CD112 can inhibit the killing effect of NK cells on TIGIT-expressing cells (Stanietsky N, Simic H, Arapovic J, et al.
  • TIGIT The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity[ J]. Proceedings of the National Academy of Sciences, 2009, 106(42):17858-17863). It has been reported that blocking PD-1 and TIGIT at the same time can enhance the killing effect of CD8+ T cells (Johnston R J, Comps-Agrar L, hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cells cell effector function[J]. Cancer cell, 2014, 26(6):923-937).
  • TIGIT acts as an immune checkpoint for NK cells, and the inhibitory receptor TIGIT during tumor development can lead to NK cell depletion, and it was demonstrated that anti-TIGIT mAb can reverse NK cell depletion and be used in a variety of tumors such as non-small cells Immunotherapy for cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, non-Hodgkin's lymphoma, B lymphoma, plasma cell carcinoma, etc. (Zhang Q, Bi J, Zheng X, et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity[J]. Nature Immunology, 2018, 19(7):723-732).
  • TIGIT and CD155 were up-regulated in the cancer tissues of hepatocellular carcinoma (HCC) patients as the degree of carcinogenesis increased from high to low.
  • TIGIT blockade alone or in combination with PD-1 blocker plus CD96 blockade has been reported to significantly reduce B16 melanoma growth in wild-type and Cd155-/- mouse models (Li XY, Das I, Lepletier A, et al.. Cd155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. J Clin Invest 2018;128:2613–25).
  • CD112R blockade alone or in combination with TIGIT blocker and/or PD-1 blockade increases the cytokine-producing capacity of TILs in ovarian, endometrioma, and lung tumors (Whelan S, Ophir E, Kotturi MF, et al.. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 + T-cell Function. Cancer Immunol Res 2019;7:257–68).
  • Anti-TIGIT antibody drugs have broad application prospects as new immune checkpoint antibody drugs, which can be used for tumor immunotherapy.
  • Tiragolumab developed by Roche, is in Phase 3, and it has been reported that TIGIT monoclonal antibody Tiragolumab combined with PD-L1 drug Tecentrip (atezolizumab) as first-line therapy is effective in the treatment of PD-L1-positive metastatic non-small cell lung cancer.
  • Tecentrip atezolizumab
  • the combination of Tiragolumab and Tecentriq was found to be well tolerated in a phase 2 clinical study in patients with NSCLC, with a 43% reduction in the risk of disease progression and a significant combination effect (Exit C.Roche to present first clinical data on novel anti-TIGIT cancer).
  • immunotherapy tiragolumab at ASCO[J] ASCO[J]
  • the inventors used a mammalian cell expression system to express recombinant human TIGIT as an antigen to immunize mice, and obtained hybridoma cells by fusing mouse spleen cells with myeloma cells.
  • the inventor obtained the hybridoma cell line LT019 by screening a large number of samples (the deposit number is CCTCC NO: C2020208).
  • the hybridoma cell line LT019 can secrete and produce a specific monoclonal antibody (named 26B12) that specifically binds to human TIGIT, and the monoclonal antibody can bind TIGIT very effectively, reducing the inhibition of TIGIT immunity.
  • the role of cells promoting T cell activity, reversing NK cell depletion, and enhancing the killing effect of immune cells on tumors.
  • the inventors creatively prepared humanized antibodies against human TIGIT (named 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4 and 26B12H4L4).
  • Antibodies of the present invention have utility in the treatment and/or prevention of tumors (eg, liver cancer, kidney cancer, brain tumor, urothelial cancer, bone tumor, cholangiocarcinoma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colon cancer Rectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphoma, B lymphoma, ovarian cancer, plasma cell cancer, endometrial cancer, prostate cancer, testicular cancer) and other diseases.
  • tumors eg, liver cancer, kidney cancer, brain tumor, urothelial cancer, bone tumor, cholangiocarcinoma, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colon cancer Rectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple myeloma, Hodgkin lymphoma, non-Hodgkin lymphom
  • One aspect of the present invention pertains to an anti-TIGIT antibody or antigen-binding fragment thereof, wherein,
  • the heavy chain variable region of the antibody comprises HCDR1-HCDR3 whose amino acid sequences are shown in SEQ ID NOs: 3-5, respectively; and the light chain variable region of the antibody comprises amino acid sequences such as SEQ ID NOs: 8-10, respectively LCDR1-LCDR3 shown.
  • the anti-TIGIT antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the variable region of the heavy chain of the antibody is selected from SEQ ID NO: 1, SEQ ID NO: 11. SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 17; and
  • amino acid sequence of the light chain variable region of the antibody is selected from the group consisting of SEQ ID NO:6, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23 and SEQ ID NO:25.
  • the anti-TIGIT antibody or antigen-binding fragment thereof wherein,
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 1
  • amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 6;
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 11
  • amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 19;
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 17, and the amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 19;
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 13
  • amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 21;
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 13
  • amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 23;
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 15, and the amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 21;
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 15, and the amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 23;
  • amino acid sequence of the variable region of the heavy chain of the antibody is shown in SEQ ID NO: 11
  • amino acid sequence of the variable region of the light chain of the antibody is shown in SEQ ID NO: 25; or
  • amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:17, and the amino acid sequence of the light chain variable region of the antibody is shown in SEQ ID NO:25.
  • the anti-TIGIT antibody or antigen-binding fragment thereof wherein the antibody comprises a non-CDR region, and the non-CDR region is from a species other than murine, For example from human antibodies.
  • the anti-TIGIT antibody or antigen-binding fragment thereof wherein the heavy chain constant region of the antibody is an Ig gamma-1 chain C region (eg NCBI ACCESSION: P01857) or Ig gamma-4 chain C region (eg NCBI ACCESSION:P01861.1); light chain constant region is Ig kappa chain C region (eg NCBI ACCESSION:P01834).
  • the heavy chain constant region of the antibody is an Ig gamma-1 chain C region (eg NCBI ACCESSION: P01857) or Ig gamma-4 chain C region (eg NCBI ACCESSION:P01861.1); light chain constant region is Ig kappa chain C region (eg NCBI ACCESSION:P01834).
  • the anti-TIGIT antibody or antigen-binding fragment thereof wherein the anti-TIGIT antibody or antigen-binding fragment thereof is selected from Fab, Fab', F(ab')2, Fd, Fv, dAb, complementarity determining region fragment, single chain antibody, humanized antibody, chimeric antibody or diabody.
  • the anti-TIGIT antibody or antigen-binding fragment thereof wherein the antibody binds TIGIT-mFc with a K D less than 4E-10 or less than 4E-11; preferably, The KD was measured by Fortebio Molecular Interaction Instrument.
  • the anti-TIGIT antibody or antigen-binding fragment thereof wherein the antibody binds TIGIT-mFc with an EC 50 of less than 1.5 nM, less than 1.2 nM or less than 1 nM; preferably , the EC 50 was measured by flow cytometry.
  • the anti-TIGIT antibody is a monoclonal antibody.
  • the anti-TIGIT antibody is a humanized antibody, a chimeric antibody, a multispecific antibody (eg, a bispecific antibody).
  • the antigen-binding fragment is selected from the group consisting of Fab, Fab', F(ab') 2 , Fd, Fv, dAb, Fab/c, complementarity determining region fragments, single chain antibodies (eg, scFv ), humanized antibodies, chimeric antibodies or bispecific antibodies.
  • the anti-TIGIT antibody or an antigen-binding fragment thereof wherein the antibody is an antibody produced by a hybridoma cell line LT019, which is deposited in the Chinese Typical Culture Collection Center (CCTCC), the deposit number is CCTCC NO: C2020208.
  • CTCC Chinese Typical Culture Collection Center
  • Another aspect of the present invention relates to an isolated nucleic acid molecule encoding an anti-TIGIT antibody or antigen-binding fragment thereof of any of the present invention.
  • Yet another aspect of the present invention relates to a vector comprising the isolated nucleic acid molecule of the present invention.
  • Yet another aspect of the present invention relates to a host cell comprising an isolated nucleic acid molecule of the present invention, or a vector of the present invention.
  • Another aspect of the present invention relates to the hybridoma cell line LT019, which is deposited in the China Center for Type Culture Collection (CCTCC), and the deposit number is CCTCC NO: C2020208.
  • CTCC China Center for Type Culture Collection
  • Still another aspect of the present invention relates to a conjugate comprising an antibody and a conjugating moiety, wherein the antibody is the anti-TIGIT antibody or an antigen-binding fragment thereof according to any one of the present invention, and the conjugating moiety is a Label for detection; preferably, the coupling moiety is a radioisotope, fluorescent substance, luminescent substance, colored substance or enzyme.
  • kits comprising the anti-TIGIT antibody or antigen-binding fragment thereof of any one of the present invention, or a conjugate of the present invention
  • the kit further includes a second antibody that specifically recognizes the antibody; optionally, the second antibody further includes a detectable label, such as a radioisotope, fluorescent substance, luminescent substance, colored substance or enzymes.
  • a detectable label such as a radioisotope, fluorescent substance, luminescent substance, colored substance or enzymes.
  • a further aspect of the present invention relates to the use of the antibody of any one of the present invention or the conjugate of the present invention in the preparation of a kit for detecting the presence or level of TIGIT in a sample.
  • Another aspect of the present invention relates to a pharmaceutical composition
  • a pharmaceutical composition comprising the anti-TIGIT antibody or antigen-binding fragment thereof of any one of the present invention or the conjugate of the present invention; optionally, the pharmaceutical composition further A pharmaceutically acceptable carrier and/or excipient is included.
  • the pharmaceutical composition further comprises one or more anti-PD-1 antibodies, or one or more anti-PD-L1 antibodies.
  • the pharmaceutical composition wherein, according to the mass of the antibody, the mass ratio of the anti-TIGIT antibody or its antigen-binding fragment to the anti-PD-1 antibody or anti-PD-L1 antibody as (1:5)-(5:1), for example: 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1 .
  • Yet another aspect of the present invention relates to a bispecific antibody comprising a first protein domain and a second protein domain, wherein:
  • the first protein functional region targets TIGIT,
  • the second protein domain targets a target other than TIGIT (eg, PD-1),
  • the first protein functional region is the antibody or antigen-binding fragment of any one of the present invention.
  • the bispecific antibody is in IgG-scFv format
  • the first protein functional domain is the antibody of any one of the present invention and is in the form of an immunoglobulin, and the second protein functional domain is a single chain antibody; or
  • the first protein functional domain is a single chain antibody
  • the second protein functional domain is an antibody in the form of an immunoglobulin.
  • the bispecific antibody wherein the antibody of any one of the present invention is in the form of immunoglobulin.
  • the bispecific antibody wherein the single chain antibody is in the form of heavy chain variable region-linker-light chain variable region.
  • the bispecific antibody wherein the first protein functional domain and the second protein functional domain are directly connected or connected by a linker; the linker is connected to the previous single chain
  • the linking fragments in the antibody can be the same or different, and the linking fragments commonly used in the art can be used.
  • the first protein functional region and the second protein functional region are independently one, two or more than two.
  • the bispecific antibody wherein the single-chain antibody is linked to the C-terminus of the two heavy chains of the antibody in the form of immunoglobulins; preferably, each heavy chain is linked a single-chain antibody.
  • Yet another aspect of the present invention relates to a combination product comprising a first product and a second product individually packaged, wherein,
  • the first product comprises the anti-TIGIT antibody or antigen-binding fragment thereof of any one of the present invention, the conjugate of the present invention, or the pharmaceutical composition of any one of the present invention;
  • the second product comprises at least one anti-PD-1 antibody or at least one anti-PD-L1 antibody;
  • the first product and the second product further independently comprise one or more pharmaceutically acceptable adjuvants (eg carriers and/or excipients);
  • one or more pharmaceutically acceptable adjuvants eg carriers and/or excipients
  • the combination product further comprises product instructions.
  • the combination product wherein, according to the mass of the antibody, the mass ratio of the anti-TIGIT antibody or its antigen-binding fragment to the anti-PD-1 antibody or the anti-PD-L1 antibody is (1:5)-(5:1), eg: 1:5, 1:4, 1:3, 1:2, 1:1, 2:1, 3:1, 4:1 or 5:1.
  • a further aspect of the present invention relates to the antibody or antigen-binding fragment thereof of any one of the present invention, the conjugate of the present invention, the bispecific antibody of any one of the present invention, any one of the present invention
  • described tumor is selected from liver cancer, kidney cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Breast Cancer, Ovarian Cancer, Colorectal Cancer, Melanoma Cancer, Pancreatic Cancer, Cervical Cancer, Multiple Myeloma, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Lymphoma , one or more of ovarian cancer, plasma cell cancer, endometrial cancer, prostate cancer, and testicular cancer.
  • Yet another aspect of the present invention relates to a method for treating and/or preventing tumors, comprising administering to a subject in need thereof an effective amount of the antibody or antigen-binding fragment thereof of any one of the present invention, the conjugate of the present invention
  • the steps of the conjugate, the bispecific antibody of any one of the present invention, the pharmaceutical composition of any one of the present invention, or the combination product of any one of the present invention preferably, the tumor Selected from liver cancer, kidney cancer, brain tumor, urothelial cancer, bone tumor, bile duct cancer, non-small cell lung cancer, small cell lung cancer, breast cancer, ovarian cancer, colorectal cancer, melanoma, pancreatic cancer, cervical cancer, multiple One or more of myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-lymphoma, ovarian cancer, plasma cell cancer, endometrial cancer, prostate cancer, and testicular cancer.
  • the liver cancer is hepatocellular carcinoma.
  • variable regions of the light and heavy chains determine antigen binding; the variable regions of each chain contain three hypervariable regions, called complementarity determining regions (CDRs) (the CDRs of the heavy chain (H) include HCDR1, HCDR2, HCDR3 , the CDRs of the light chain (L) comprise LCDR1, LCDR2, LCDR3; it is named by Kabat et al., see Bethesda M.d., Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 1991; 1-3:91-3242.
  • CDRs complementarity determining regions
  • the CDRs can also be defined by the IMGT numbering system, see Ehrenmann, Francois, Quentin Kaas, and Marie-Paule Lefranc.
  • IMGT/3Dstructure-DB and IMGT/DomainGapAlign a database and a tool for immunoglobulins or antibodies, T cell receptors , MHC, IgSF and MhcSF. Nucleic acids research 2009;38(suppl_1):D301-D307.
  • amino acid sequences of the CDR regions of the monoclonal antibody sequences are analyzed according to the IMGT definitions by technical means well known to those skilled in the art, for example, by the VBASE2 database.
  • 26B12, 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4 and 26B12H4L4 have the same CDRs:
  • amino acid sequences of the three CDR regions in the variable region of its heavy chain are as follows:
  • HCDR3 ARLDYGNYGGAMDY (SEQ ID NO: 5);
  • amino acid sequences of the three CDR regions of the light chain variable region are as follows:
  • LCDR1 QHVSTA (SEQ ID NO: 8)
  • LCDR2 SAS (SEQ ID NO: 9)
  • LCDR3 QQHYITPWT (SEQ ID NO: 10).
  • TIGIT when referring to the amino acid sequence of TIGIT (NCBI GenBank ID: NP_776160.2), it includes the full length of the TIGIT protein, either the extracellular immunoglobulin variable region (IgV) domain or the containing cell Fragments of outer immunoglobulin variable region (IgV) domains; also include fusion proteins of TIGIT, eg, fragments fused to Fc protein fragments (mFc or hFc) of mouse or human IgG.
  • fusion proteins of TIGIT eg, fragments fused to Fc protein fragments (mFc or hFc) of mouse or human IgG.
  • mFc or hFc Fc protein fragments
  • TIGIT protein or “TIGIT” shall include all such sequences, including the sequences shown as well as natural or artificial variants thereof. Also, when describing a sequence fragment of a TIGIT protein, it includes not only the sequence fragment, but also the corresponding sequence fragment in natural or artificial variants thereof.
  • EC 50 refers to the concentration for 50% of maximal effect, which refers to the concentration that elicits 50% of the maximal effect.
  • antibody refers to an immunoglobulin molecule generally composed of two pairs of polypeptide chains, each pair having one "light” (L) chain and one "heavy” (H) chain.
  • Antibody light chains can be classified as kappa and lambda light chains.
  • Heavy chains can be classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively.
  • the variable and constant regions are linked by a "J" region of about 12 or more amino acids, and the heavy chain also contains a "D" region of about 3 or more amino acids.
  • Each heavy chain consists of a heavy chain variable region ( VH ) and a heavy chain constant region ( CH ).
  • the heavy chain constant region consists of 3 domains ( CH1 , CH2 and CH3 ).
  • Each light chain consists of a light chain variable region ( VL ) and a light chain constant region ( CL ).
  • the light chain constant region consists of one domain, CL .
  • the constant regions of the antibodies mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (eg, effector cells) and the first component (Clq) of the classical complement system.
  • the VH and VL regions can also be subdivided into regions of high variability called complementarity determining regions (CDRs) interspersed with more conserved regions called framework regions (FRs).
  • CDRs complementarity determining regions
  • Each VH and VL consists of 3 CDRs and 4 FRs arranged in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from amino terminus to carboxy terminus.
  • the assignment of amino acids to regions or domains follows the Kabat Sequences of Proteins of Immunological Interest (National Institutes of Health, Bethesda Md (1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 1987; 196:901-917; Chothia et al.
  • IMGT/3Dstructure-DB and IMGT/DomainGapAlign a database and a tool for immunoglobulins or antibodies, T Definition of cell receptors, MHC, IgSF and MhcSF.” Nucleic acids research 2009;38(suppl_1):D301-D307.
  • antibody is not limited by any particular method of producing an antibody. For example, it includes, in particular, recombinant antibodies, monoclonal antibodies and polyclonal antibodies.
  • Antibodies can be of different isotypes, eg, IgG (eg, IgGl, IgG2, IgG3, or IgG4 subtype), IgAl, IgA2, IgD, IgE, or IgM antibodies.
  • IgG eg, IgGl, IgG2, IgG3, or IgG4 subtype
  • IgAl IgA2, IgD, IgE, or IgM antibodies.
  • the term "antigen-binding fragment" of an antibody refers to a polypeptide comprising a fragment of a full-length antibody that retains the ability to specifically bind to, and/or compete with, the same antigen to which the full-length antibody binds Specific binding to an antigen, which is also referred to as an "antigen binding moiety".
  • an antigen binding moiety which is also referred to as an "antigen binding moiety”.
  • antigen-binding fragments include Fab, Fab', F(ab') 2 , Fd, Fv, dAb, and complementarity determining regions (CDRs) Fragments, single chain antibodies (eg, scFvs), chimeric antibodies, diabodies, and polypeptides comprising at least a portion of the antibody sufficient to confer specific antigen-binding ability to the polypeptide.
  • CDRs complementarity determining regions
  • the term “Fd fragment” means an antibody fragment composed of VH and CH1 domains;
  • the term “Fv fragment” means an antibody fragment composed of the one-armed VL and VH domains of an antibody Antibody fragments;
  • the term “dAb fragment” means an antibody fragment composed of VH domains (Ward et al., Nature 341:544-546 (1989));
  • the term “Fab fragment” means a fragment composed of VL , VH , C Antibody fragments composed of L and CH1 domains;
  • the term “ F (ab') 2 fragment” means an antibody fragment comprising two Fab fragments linked by a disulfide bridge on the hinge region.
  • the antigen-binding fragment of an antibody is a single-chain antibody (eg, scFv) in which the VL and VH domains are paired to form a monovalent molecule by linkers that enable it to be produced as a single polypeptide chain (see, eg, Bird et al, Science 242:423-426 (1988) and Huston et al, Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988)).
  • scFv molecules may have the general structure: NH2 - VL -linker- VH -COOH or NH2 - VH -linker- VL -COOH.
  • Suitable prior art linkers consist of repeated GGGGS amino acid sequences or variants thereof.
  • a linker with the amino acid sequence (GGGGS) 4 can be used, but also variants thereof (Holliger et al. (1993), Proc. Natl. Acad. Sci. USA 90:6444-6448).
  • Other linkers that can be used in the present invention are described by Alfthan et al. (1995), Protein Eng. 8:725-731, Choi et al. (2001), Eur. J. Immunol. 31: 94-106, Hu et al. (1996), Cancer Res. 56:3055-3061, described by Kipriyanov et al. (1999), J. Mol. Biol. 293:41-56 and Roovers et al. (2001), Cancer Immunol.
  • the antigen-binding fragment of an antibody is a diabody, i.e., a diabody, in which the VH and VL domains are expressed on a single polypeptide chain, but linkers that are too short are used to allow the Pairing between the two domains forces the domains to pair with the complementary domains of the other chain and create two antigen binding sites (see, e.g., Holliger P. et al., Proc. Natl. Acad. Sci. USA 90:6444 -6448 (1993), and Poljak RJ et al., Structure 2:1121-1123 (1994)).
  • the antigen-binding fragment of an antibody is a "bispecific antibody", which refers to a conjugate formed by a first antibody (fragment) and a second antibody (fragment) or antibody analog through a coupling arm, coupled
  • the means of association include, but are not limited to, chemical reaction, gene fusion and enzymatic catalysis.
  • Antigen-binding fragments of antibodies may be "multispecific antibodies” including, for example, trispecific antibodies, which are antibodies with three different antigen-binding specificities, and tetraspecific antibodies, which are antibodies with four different antigen-binding specificities of antibodies.
  • a designed ankyrin repeat protein (DARPin), linked to an IgG antibody, a scFv-Fc antibody fragment, or a combination thereof, such as CN104341529A.
  • Anti-IL-17a fynomers bind to anti-IL-6R antibodies, as in WO2015141862A1.
  • a given antibody such as the monoclonal antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3 provided herein, can be obtained from a given antibody using conventional techniques known to those skilled in the art (eg, recombinant DNA technology or enzymatic or chemical fragmentation). , 26B12H1L4, and 26B12H4L4) to obtain antigen-binding fragments of antibodies (eg, the antibody fragments described above), and screen the antibodies for specificity in the same manner as for intact antibodies.
  • conventional techniques known to those skilled in the art eg, recombinant DNA technology or enzymatic or chemical fragmentation.
  • 26B12H1L4, and 26B12H4L4 to obtain antigen-binding fragments of antibodies (eg, the antibody fragments described above), and screen the antibodies for specificity in the same manner as for intact antibodies.
  • the terms “monoclonal antibody” and “monoclonal antibody” refer to an antibody or a fragment of an antibody from a population of highly homologous antibody molecules, that is, excluding natural mutations that may arise spontaneously, A population of identical antibody molecules.
  • Monoclonal antibodies are highly specific for a single epitope on an antigen.
  • Polyclonal antibodies are relative to monoclonal antibodies, which generally comprise at least two or more different antibodies that generally recognize different epitopes on an antigen.
  • Monoclonal antibodies can usually be obtained using the hybridoma technology first reported by Kohler et al. ( G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity [J]. nature, 1975; 256(5517): 495), but can also be obtained by recombinant DNA technology (eg, see US Patent 4,816,567).
  • humanized antibody refers to the replacement of all or part of the CDR regions of a human immunoglobulin (acceptor antibody) with the CDR regions of a non-human antibody (donor antibody)
  • the antibody or antibody fragment of which the donor antibody can be a non-human (eg, mouse, rat or rabbit) antibody with the desired specificity, affinity or reactivity.
  • some amino acid residues in the framework region (FR) of the acceptor antibody can also be replaced by amino acid residues of corresponding non-human antibodies, or by amino acid residues of other antibodies, to further improve or optimize the performance of the antibody.
  • isolated refers to artificially obtained from the natural state. If an "isolated” substance or component occurs in nature, it may be due to a change in its natural environment, or separation of the substance from its natural environment, or both. For example, a certain unisolated polynucleotide or polypeptide naturally exists in a living animal, and the same polynucleotide or polypeptide with high purity isolated from this natural state is called isolated of.
  • isolated or isolated
  • the term "vector” refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted.
  • the vector can express the protein encoded by the inserted polynucleotide, the vector is called an expression vector.
  • the vector can be introduced into a host cell by transformation, transduction or transfection, so that the genetic material elements carried by it can be expressed in the host cell.
  • Vectors are well known to those skilled in the art and include, but are not limited to: plasmids; phagemids; cosmids; artificial chromosomes, such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1 derived artificial chromosomes (PACs) ; Phage such as ⁇ phage or M13 phage and animal viruses.
  • YACs yeast artificial chromosomes
  • BACs bacterial artificial chromosomes
  • PACs P1 derived artificial chromosomes
  • Animal viruses that can be used as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (eg, herpes simplex virus), poxviruses, baculoviruses, papillomaviruses, papillomaviruses Polyoma vacuolar virus (eg SV40).
  • retroviruses including lentiviruses
  • adenoviruses eg, adeno-associated viruses
  • herpesviruses eg, herpes simplex virus
  • poxviruses baculoviruses
  • papillomaviruses papillomaviruses
  • Polyoma vacuolar virus eg SV40
  • a vector may contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription initiation sequences, enhancer sequences, selection elements, and
  • the term "host cell” refers to a cell that can be used to introduce a vector, including, but not limited to, prokaryotic cells such as Escherichia coli or Bacillus subtilis, fungal cells such as yeast cells or Aspergillus, etc., Insect cells such as S2 Drosophila cells or Sf9, or animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, GS cells, BHK cells, HEK 293 cells or human cells.
  • prokaryotic cells such as Escherichia coli or Bacillus subtilis
  • fungal cells such as yeast cells or Aspergillus, etc.
  • Insect cells such as S2 Drosophila cells or Sf9
  • animal cells such as fibroblasts, CHO cells, COS cells, NSO cells, HeLa cells, GS cells, BHK cells, HEK 293 cells or human cells.
  • an antibody that specifically binds to an antigen refers to an antibody that is less than about 10-5 M, such as less than about 10-6 M, 10-7 M, Binds the antigen with an affinity (K D ) of 10-8 M, 10-9 M, or 10-10 M or less.
  • KD refers to the dissociation equilibrium constant for a particular antibody-antigen interaction, which is used to describe the binding affinity between an antibody and an antigen.
  • antibodies exhibit a dissociation equilibrium constant (K D ) of less than about 10-5 M, eg, less than about 10-6 M, 10-7 M, 10-8 M, 10-9 M, or 10-10 M or less Binds antigen (eg, TIGIT protein).
  • KD can be determined using methods known to those skilled in the art, eg, using a Fortebio Molecular Interactometer.
  • amino acids are generally represented by one-letter and three-letter abbreviations well known in the art.
  • alanine can be represented by A or Ala.
  • the term "pharmaceutically acceptable carrier and/or excipient” refers to a carrier and/or excipient that is pharmacologically and/or physiologically compatible with the subject and the active ingredient, It is well known in the art (see e.g. Remington's Pharmaceutical Sciences. Edited by Gennaro AR, 19th ed. Pennsylvania: Mack Publishing Company, 1995) and includes, but is not limited to: pH adjusters, surfactants, adjuvants, ionic strength enhancers agent.
  • pH adjusting agents include but are not limited to phosphate buffers; surfactants include but are not limited to cationic, anionic or nonionic surfactants such as Tween-80; ionic strength enhancers include but are not limited to sodium chloride.
  • the term "effective amount" refers to an amount sufficient to obtain, or at least partially obtain, the desired effect.
  • a disease-prophylactically effective amount refers to an amount sufficient to prevent, arrest, or delay the onset of a disease (eg, a tumor);
  • a therapeutically-effective amount refers to an amount sufficient to cure or at least partially prevent the development of a disease in a patient already suffering from the disease. The amount of disease and its complications.
  • TIGIT protein when referring to the amino acid sequence of a TIGIT protein (NCBI GenBank: NP_776160.2), it includes the full length of the TIGIT protein, or the extracellular fragment TIGIT ECD of TIGIT or a fragment comprising TIGIT ECD; also includes A full-length fusion protein of TIGIT protein or a fusion protein of TIGIT ECD, eg, a fragment fused to an Fc protein fragment (mFc or hFc) of mouse or human IgG.
  • mutations or variations including but not limited to substitutions, deletions and/or additions
  • the term "addition", protein” shall include all such sequences, including natural or artificial variants thereof.
  • a sequence fragment of a TIGIT protein when described, it also includes the corresponding sequence fragment in its natural or artificial variant.
  • hybridomas As used herein, the terms “hybridoma” and “hybridoma cell line” are used interchangeably, and when referring to the terms “hybridoma” and “hybridoma cell line”, it also includes subclones of hybridomas and progeny cells.
  • first and second are for the purpose of denoting distinction or expressing clarity, and are not typical meaning in order.
  • the monoclonal antibody of the invention can specifically bind to TIGIT well and has a strong affinity, thereby reducing the effect of TIGIT on inhibiting immune cells, promoting the activity of T cells, reversing NK cell exhaustion, and enhancing the killing effect of immune cells on tumors.
  • Figure 1 Binding activity test results of 26B12H1L1, 26B12H2L2, 26B12H2L3 and 26B12H3L2 antibodies to TIGIT-mFc.
  • FIG. 1 Binding activity test results of 26B12H3L3, 26B12H1L4, 26B12H4L1 and 26B12H4L4 antibodies to TIGIT-mFc.
  • FIG. 3 Activity assay results of 26B12H1L1, 26B12H2L2, 26B12H2L3 and 26B12H3L2 antibodies competing with human CD155-hFc-Biotin for binding to TIGIT-mFc.
  • Figure 4 Activity assay results of 26B12H3L3, 26B12H1L4, 26B12H4L1 and 26B12H4L4 antibodies competing with human CD155-hFc-Biotin for binding to TIGIT-mFc.
  • Figure 5 Graph of the detection result of affinity constant between 26B12H3L3 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 6 Graph of the detection result of affinity constant between 26B12H1L1 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 7 Graph of the detection result of affinity constant between 26B12H2L2 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 8 Graph of the detection result of affinity constant between 26B12H2L3 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 9 Graph of the detection result of affinity constant between 26B12H3L2 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 10 Graph of the detection result of affinity constant between 26B12H4L4 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 11 Graph of the detection result of affinity constant between 26B12H1L4 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 12 Graph of the detection result of affinity constant between 26B12H4L1 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 13 Graph of the detection result of affinity constant between RG6058 and TIGIT-mFc.
  • concentrations of antibodies added to each pair of curves from top to bottom in the figure were 5nM, 1.67nM, 0.557nM, 0.185nM, and 0.06nM, respectively.
  • Figure 14 FACS detection of the binding activity of humanized antibodies 26B12H2L2 and RG6058 to 293T-TIGIT cell membrane surface antigen TIGIT.
  • Figure 15 FACS detection of the activity of humanized antibodies 26B12H2L2 and RG6058 to compete with CD155 for binding to TIGIT on the cell membrane surface of 293T-TIGIT.
  • Figure 16 FACS detection of the activity of humanized antibodies 26B12H2L2 and RG6058 to compete with CD112 for binding to TIGIT on the cell membrane surface of 293T-TIGIT.
  • Figure 17 Detection of the amount of IL-2 secreted after adding TIGIT antibody to Jurkat-TIGIT and HT1080-aCD3 scFv cell systems.
  • Figure 18 The effect of hTIGIT-BALB/c transgenic mouse CT26 tumor model.
  • Figure 19 Changes in body weight of hTIGIT-BALB/c transgenic mouse CT26 tumor model.
  • the hybridoma cell line LT019 was deposited in the China Center for Type Culture Collection (CCTCC) on October 23, 2020, with the deposit number CCTCC NO: C2020208, and the deposit address is China. Wuhan. Wuhan University, zip code: 430072.
  • the present invention relates to the following sequences 1-26:
  • HCDR3 ARLDYGNYGGAMDY (SEQ ID NO: 5)
  • the BALB/c mice used were purchased from the Guangdong Provincial Medical Laboratory Animal Center.
  • the used positive control antibody RG6058 its sequence can refer to sequence 34 and sequence 36 in Chinese published patent CN108290946A.
  • the 293T-TIGIT cell line used was constructed by Zhongshan Kangfang Biopharmaceutical Co., Ltd.
  • the 293T-TIGIT cell line was prepared by viral transfection of HEK293T cells, and the virus was prepared using 3rd Generation Lentiviral Systems, see, for example, A Third Generation Lentivirus Vector with a Conditional Packaging System. Dull T, Zufferey R, Kelly M, Mandel RJ , Nguyen M, Trono D, and Naldini L.J Virol. 1998.72 (11): 8463-8471.
  • the lentiviral expression vector used is pCDH-CMV-PD-1FL-Puro (wherein TIGIT, Genebank ID: NP_776160.2;
  • the vector pCDH-CMV-Puro was purchased from Youbao Bio, product number: VT1480).
  • the antigen used to prepare the anti-TIGIT antibody was human TIGIT-mFc (TIGIT is Genbank ID: NP_776160.2).
  • the spleen cells of the immunized mice were fused with mouse myeloma cells to prepare hybridoma cells.
  • human TIGIT-mFc as an antigen, the hybridoma cells were screened by indirect ELISA method to obtain hybridoma cells that can secrete antibodies that specifically bind to TIGIT.
  • the hybridoma cells obtained by screening were subjected to a limiting dilution method to obtain stable hybridoma cell lines.
  • the above hybridoma cell lines were named as hybridoma cell line LT019, respectively, and the monoclonal antibody secreted by them was named as 26B12.
  • the hybridoma cell line LT019 was deposited in the China Center for Type Culture Collection (CCTCC) on October 23, 2020, with the deposit number CCTCC NO: C2020208, and the deposit address is China. Wuhan. Wuhan University, zip code: 430072.
  • the LT019 cell line prepared above was cultured in CD medium (Chemical Defined Medium, containing 1% penicillin-streptomycin) under the conditions of 5% CO 2 and 37°C. After 7 days, the cell culture supernatant was collected, and the antibody 26B12 was prepared by high-speed centrifugation, vacuum filtration with a microporous membrane, and purification using a HiTrap protein A HP column.
  • CD medium Chemical Defined Medium, containing 1% penicillin-streptomycin
  • mRNA was extracted from the LT019 cell line cultured in Example 1 according to the method of the Cultured Cell Bacterial Total RNA Extraction Kit (Tiangen, Cat. No. DP430).
  • the PCR amplification product was directly cloned by TA, and the specific operation was carried out by referring to the instructions of the pEASY-T1 Cloning Kit (Transgen CT101).
  • the nucleic acid sequence of the heavy chain variable region is shown in SEQ ID NO: 2, and the fragment is 363 bp long.
  • the encoded amino acid sequence is shown in SEQ ID NO: 1, and the length is 121 amino acids.
  • sequence of heavy chain HCDR1 is shown in SEQ ID NO:3
  • sequence of HCDR2 is shown in SEQ ID NO:4
  • sequence of HCDR3 is shown in SEQ ID NO:5.
  • the nucleic acid sequence of the light chain variable region is shown in SEQ ID NO: 7, and the length is 321 bp.
  • the encoded amino acid sequence is shown in SEQ ID NO: 6, and the length is 107 amino acids.
  • the sequence of light chain LCDR1 is shown in SEQ ID NO:8, the sequence of LCDR2 is shown in SEQ ID NO:9, and the sequence of LCDR3 is shown in SEQ ID NO:10.
  • the antibody model was simulated by computer, and then mutations were designed according to the model to obtain the antibodies 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4 and 26B12H4L4.
  • Variable region sequence antibody constant region sequence, from the database of NCBI, heavy chain constant region adopts Ig gamma-1 chain C region, ACCESSION: P01857; light chain constant region is Ig kappa chain C region, ACCESSION: P01834).
  • the length of the nucleic acid sequence of the heavy chain variable region is all 363bp, and the length of the encoded amino acid sequence is all 121aa;
  • the lengths of the nucleic acid sequences of the regions are all 321bp, and the lengths of the encoded amino acid sequences are all 107aa.
  • HCDR1 The sequence of HCDR1 is shown in SEQ ID NO:3, the sequence of HCDR2 is shown in SEQ ID NO:4, and the sequence of HCDR3 is shown in SEQ ID NO:5;
  • the sequence of LCDR1 is shown in SEQ ID NO:8, the sequence of LCDR2 is shown in SEQ ID NO:9, and the sequence of LCDR3 is shown in SEQ ID NO:10.
  • the heavy chain constant region adopts the Ig gamma-1 chain C region, ACCESSION: P01857; the light chain constant region adopts the Ig kappa chain C region, ACCESSION: P01834.
  • the recombinant plasmids containing the corresponding light and heavy chains were designed to combine the genes (pcDNA3.1-26B12H1/pcDNA3.1-26B12L1, pcDNA3.1-26B12H4/pcDNA3.1-26B12L1, pcDNA3.1-26B12H2/pcDNA3.1-26B12L2 , pcDNA3.1-26B12H3/pcDNA3.1-26B12L2, pcDNA3.1-26B12H2/pcDNA3.1-26B12L3, pcDNA3.1-26B12H3/pcDNA3.1-26B12L3, pcDNA3.1-26B12H1/pcDNA3.1-26B12L4 and pcDNA3 .1-26B12H4/pcDNA3.1-26B12L4) were co-transfected into 293F cells, and then the culture medium was collected for purification.
  • an endotoxin-free expression plasmid was prepared and the plasmid was transiently transfected into HEK293 cells for antibody expression. After 7 days of culture, the cell culture medium was collected, and a Protein A column was used for affinity purification to obtain humanized antibodies.
  • Example 4 ELISA method to measure the binding activity of antibody to antigen TIGIT-mFc
  • the antibody dilution gradient is shown in Table 1 and Table 2.
  • the ELISA plate with the antibody to be tested was incubated at 37°C for 30 minutes, and the plate was washed 3 times with PBST after the incubation. After washing the plate, add HRP-labeled goat anti-human IgG Fc secondary antibody working solution diluted at a ratio of 1:5000, and incubate at 37°C for 30 minutes. After incubation, the plate was washed 4 times with PBST, and then TMB (Neogen, 308177) was added for 4 min in the dark for color development, and stop solution was added to stop the color reaction. Immediately put the ELISA plate into the microplate reader, select 450nm light wavelength to read the OD value of each well of the ELISA plate. The data were analyzed and processed with SoftMax Pro 6.2.1 software.
  • FIGS. 1 and 2 The results of binding of the antibody to the antigen TIGIT-mFc are shown in FIGS. 1 and 2 .
  • the OD values of each dose are shown in Table 1 and Table 2. Taking the antibody concentration as the abscissa and the absorbance value as the ordinate, curve fitting was performed to calculate the binding EC 50 of the antibody to the antigen. The results are shown in Table 1, Table 2 and Figures 1 and 2.
  • Table 1 Binding activity test results of 26B12H1L1, 26B12H2L2, 26B12H2L3, 26B12H3L2 and RG6058 to TIGIT-mFc
  • Table 2 Binding activity test results of 26B12H3L3, 26B12H1L4, 26B12H4L1, 26B12H4L4 and RG6058 to TIGIT-mFc
  • Example 5 Competitive ELISA method to determine the competitive binding of antibody and CD155-hFc-Biotin Activity of TIGIT-mFc
  • TIGIT-mFc 2 ⁇ g/mL was coated on the ELISA plate and incubated at 4°C overnight. After the incubation, the antigen-coated ELISA plate was rinsed once with PBST, and then the 1% BSA in PBST solution was used as the ELISA plate blocking solution for 2 hours. After the ELISA plate was blocked, the plate was washed 3 times with PBST. Add the antibody diluted in PBST solution to the microtiter plate. The antibody concentration is shown in Table 3 and Table 4. After 10 minutes of incubation at room temperature, an equal volume of 2 ⁇ g/mL (final concentration of 1 ⁇ g/mL) CD155-hFc-Biotin was added.
  • the ELISA plate was incubated at 37°C for 30 minutes, and the plate was washed 3 times with PBST after the incubation. After washing the plate, add SA-HRP working solution diluted at a ratio of 1:4000, and incubate at 37°C for 30 minutes. After incubation, the plate was washed 4 times with PBST, TMB (Neogen, 308177) was added for 5 min in the dark for color development, and stop solution was added to stop the color reaction. Immediately put the ELISA plate into the microplate reader, select 450nm light wavelength to read the OD value of each well of the ELISA plate. The data were analyzed and processed with SoftMax Pro 6.2.1 software.
  • Table 3 and Table 4 show the results of the activity of the antibody competing with CD155-hFc-Biotin for binding to TIGIT-mFc. Taking the antibody concentration as the abscissa and the absorbance value as the ordinate, curve fitting was performed, and the EC 50 of the antibody competing with CD155-hFc-Biotin for binding to TIGIT-mFc was calculated. The results are shown in Table 3 and Table 4, Figure 3 and Figure 4 below.
  • 26B12H1L1, 26B12H4L1, 26B12H2L2, 26B12H3L2, 26B12H2L3, 26B12H3L3, 26B12H1L4 and 26B12H4L4 had potent functions to compete with CD155-hFc-Biotin for binding to TIGIT-mFc.
  • Example 6 Determination of humanized antibody 26B12H3L3, 26B12H1L1, 26B12H2L2, 26B12H2L3, 26B12H3L2, 26B12H4L4, 26B12H1L4, Kinetic parameters of 26B12H4L1 and RG6058 binding to the antigen TIGIT-mFc
  • the sample dilution buffer was PBS, 0.02% Tween-20, 0.1% BSA, pH 7.4.
  • TIGIT-mFc was immobilized on the AMC sensor at a concentration of 3 ⁇ g/mL for 50s, the sensor was equilibrated in the buffer for 60s, and the TIGIT-mFc immobilized on the sensor was bound to the antibody at a concentration of 0.06-5nM (three-fold dilution) , time 120s, protein dissociation in buffer, time 300s.
  • the detection temperature is 37 degrees
  • the detection frequency is 0.3 Hz
  • the vibration rate of the sample plate is 1000 rpm. Data were analyzed with a 1:1 model fit to obtain affinity constants.
  • each TIGIT antibody to TIGIT-mFc was in descending order: 26B12H2L2, 26B12H4L1, 26B12H1L1, RG6058, 26B12H4L4, 26B12H1L4, 26B12H2L3, 26B12H3L2, 26B12H3L3.
  • the affinity of humanized antibodies 26B12H2L2, 26B12H4L1 and 26B12H1L1 is stronger than that of positive drug RG6058, while the affinity of 26B12H4L4 is comparable to that of positive drug RG6058.
  • Example 7 FACS detection of humanized antibodies 26B12H2L2 and RG6058 and 293T-TIGIT cell membrane Binding activity of the surface antigen TIGIT
  • the TIGIT vector plenti6.3/V5-TIGITFL-BSD (the vector pLenti6.3 was purchased from Invitrogen) was transfected into 293T cells, and the cell line 293T-TIGIT cells stably expressing TIGIT was obtained by screening.
  • 293T-TIGIT cells (DMEM+10%FBS) were collected, centrifuged for 5 minutes, removed the supernatant, resuspended, counted and the viability (P7, 95.79%), diluted the cells, and added 30w cells to each well of a transparent 96-well plate with a sharp bottom , add 200 ⁇ L of 1% PBSA to each tube, centrifuge for 5 min, and remove the supernatant.
  • Table 6 FACS detection of the binding activity of humanized antibodies 26B12H2L2 and RG6058 to 293T-TIGIT cell membrane surface antigen TIGIT-
  • the experimental results are shown in Table 6 and Figure 14.
  • the EC 50 of the positive control antibody RG6058 binding to the cell membrane surface antigen TIGIT was 1.257 nM, while the EC 50 of the humanized antibody 26B12H2L2 binding to the cell membrane surface antigen TIGIT- was 0.917 nM.
  • Example 8 FACS detection of humanized antibodies 26B12H2L2 and RG6058 with CD155 or CD112 Competitive binding activity of 293T-TIGIT cell membrane surface antigen TIGIT
  • Table 7 FACS detection of humanized antibodies 26B12H2L2 and RG6058 competing with CD155 for binding to 293T-TIGIT cell membrane surface antigen TIGIT
  • Table 8 FACS detection of humanized antibodies 26B12H2L2 and RG6058 competing with CD112 for binding to 293T-TIGIT cell membrane surface antigen TIGIT
  • Example 9 Addition of TIGIT antibody to Jurkat-TIGIT and HT1080-aCD3scFv cell systems mixed lymphoid reaction
  • the TIGIT vector plenti6.3/V5-TIGITFL-BSD (the vector pLenti6.3 was purchased from Invitrogen) was transfected into Jurkat cells, and the cell line Jurkat-TIGIT cells stably expressing TIGIT was obtained after screening; the anti-CD3 antibody vector pCDH-aCD3scFv-puro (The vector pCDH-CMV-MCS-EF1-Puro was purchased from Youbao Bio) into HT-1080 cells, and the cell line HT1080-aCD3scFv cells stably expressing anti-CD3scFv on the cell membrane was obtained after screening.
  • Jurkat-TIGIT and HT1080-aCD3scFv cells in logarithmic growth phase were collected, in 96-well plates, 5W cells per well for Jurkat-TIGIT and 1W cells per well for HT1080-aCD3scFV.
  • Add diluted antibody final concentration of 10nM, 50nM, 250nM
  • anti-human CD28 antibody 3 ⁇ g/mL
  • Example 10 Effect of 26B12H2L2 on xenografted tumors in hTigit-BALB/c transgenic mice inoculated with CT26 mice Therapeutic effect
  • CT26 cells mouse colon cancer cell line, purchased from ATCC
  • the specific steps of the experiment are: 50 million/ml CT26 cells are inoculated with 100 ⁇ l of each mouse to establish a mouse tumor model.
  • control group G1 The same type of control group G1, the dosage is 20 mg/kg, the administration method is intraperitoneal injection (i.p.), twice a week;
  • the experimental group G2 was administered at a dose of 4 mg/kg, administered by intraperitoneal injection (i.p.), twice a week;
  • the experimental group G3 was administered at a dose of 20 mg/kg by intraperitoneal injection (i.p.), twice a week, and
  • the positive control group G4 was administered at a dose of 20 mg/kg by intraperitoneal injection (i.p.), twice a week.
  • 26B12H2L2 has a strong pharmacological effect on the CT26 tumor model of hTIGIT-BALB/c transgenic mice, and the effect is comparable to that of RG6058; 26B12H2L2 has the potential for the treatment and/or prevention of tumors, especially colon cancer.
  • 26B12H2L2 had no effect on the body weight of hTIGIT-BALB/c transgenic mice as a CT26 tumor model, indicating that the 26B12H2L2 antibody did not produce toxic side effects in mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

一种抗TIGIT抗体、其药物组合物及用途。涉及抗TIGIT抗体或其抗原结合片段，其中，所述抗体的重链可变区包含氨基酸序列分别如SEQ ID NOs:3-5所示的HCDR1-HCDR3；并且所述抗体的轻链可变区包含氨基酸序列分别如SEQ ID NOs:8-10所示的LCDR1-LCDR3。抗体能够有效地结合TIGIT，具有应用于肿瘤防治的潜力。

Description

抗TIGIT抗体、其药物组合物及用途 技术领域
本发明属于医药领域，涉及一种抗TIGIT抗体、其药物组合物及用途。具体地，本发明涉及一种抗TIGIT的单克隆抗体。
背景技术
TIGIT(T cell Ig and ITIM domain,又称为WUCAM，Vstm3，VSIG9)是脊髓灰质炎病毒受体(PVR)/Nectin家族的成员。TIGIT由细胞外免疫球蛋白可变区(IgV)结构域，I型跨膜结构域和具有经典免疫受体酪氨酸抑制基序(ITIM)和免疫球蛋白酪氨酸尾(ITT)基序的细胞内结构域组成。TIGIT在淋巴细胞特别是在效应和调节性CD4+T细胞、滤泡辅助CD4+T细胞和效应CD8+T细胞以及自然杀伤(NK)细胞中高表达(Yu X,Harden K,Gonzalez L C,et al.The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells[J].Nature immunology,2009,10(1):48)。
CD155(又称为PVR、Necl5或Tage4)、CD112(又称为PVRL2/nectin 2)和CD113(又称为PVRL3)是TIGIT结合的配体(Martinet L,Smyth M J.Balancing natural killer cell activation through paired receptors[J].Nature Reviews Immunology,2015,15(4):243-254.)，其中CD155是TIGIT的高亲和力配体。在NK细胞中，TIGIT结合配体CD155和CD112可以抑制NK细胞对TIGIT高表达细胞的杀伤作用(Stanietsky N,Simic H,Arapovic J,et al.The interaction of TIGIT with PVR and PVRL2inhibits human NK cell cytotoxicity[J].Proceedings of the National Academy of Sciences,2009,106(42):17858-17863)。而有报道发现在同时阻断PD-1和TIGIT时，可以增强CD8+T细胞的杀伤作用(Johnston R J,Comps-Agrar L,Hackney J,et al.The immunoreceptor TIGIT regulates antitumor and antiviral CD8+T cell effector function[J].Cancer cell,2014,26(6):923-937)。在最新的研究中发现，TIGIT作为NK细胞的免疫检查点，肿瘤发展过程中抑制性受体TIGIT可导致NK细胞耗竭，并证明抗TIGIT单抗可逆转NK细胞耗竭并用于多种肿瘤例如非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素瘤、胰腺癌、宫颈瘤、多发性骨髓瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、浆细胞癌等的免疫治疗(Zhang Q,Bi J,Zheng X,et al. Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity[J].Nature immunology,2018,19(7):723-732)。
随着癌变程度由高到低，肝细胞癌(HCC)患者的癌组织中TIGIT和CD155的表达水平上调。HCC术后患者外周血中TIGIT+cd4+T细胞和TIGIT+Treg细胞频率降低。TIGIT表达增加与AFP水平呈正相关。这些结果表明，共抑制受体TIGIT可能参与HCC的发病机制，并代表了HCC诊断和治疗的新靶点(Duan Xiangguo,Liu Juanxi,Cui Jianjian et al.Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma.[J].Mol Med Rep,2019,20:3773-3781.)。
此外有报道，TIGIT阻断剂单独或与PD-1阻滞剂联合使用再加上CD96阻断剂，可以显著降低野生型和Cd155-/-小鼠模型中B16黑色素瘤的生长(Li X-Y,Das I,Lepletier A,et al..Cd155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms.J Clin Invest 2018；128:2613–25)。CD112R阻断剂单独或与TIGIT阻断剂和/或PD-1阻断剂联合使用，能增加卵巢瘤、子宫内膜瘤和肺肿瘤中TIL产生细胞因子的能力(Whelan S,Ophir E,Kotturi MF,et al..PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8 +T-cell Function.Cancer Immunol Res 2019；7:257–68)。
抗TIGIT抗体药物作为新型免疫检查点抗体药物具有广泛的应用前景，可用于肿瘤的免疫治疗。罗氏制药(Roche)研发的Tiragolumab已处于临床3期阶段，并且据报道TIGIT单抗Tiragolumab联合PD-L1药物Tecentrip(阿特珠单抗Atezolizumab)作为一线疗法，在治疗PD-L1阳性转移性非小细胞肺癌(NSCLC)患者的2期临床研究中发现Tiragolumab与Tecentriq的组合耐受性良好，疾病进展风险下降43％，联用效果显著(Exit C.Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO[J])。
然而，目前现有的抗人TIGIT抗体药物的亲和力较低，尚缺少具有高亲和力的抗TIGIT抗体。
因此，开发与TIGIT具有高亲和力的抗体药物，用于自身免疫疾病的治疗，使其具有更好的治疗效果、更低的毒副作用，具有非常重要的意义。
发明内容
本发明人经过深入的研究和创造性的劳动，利用哺乳动物细胞表达系统表达出重组的人TIGIT作为抗原免疫小鼠，经小鼠脾脏细胞与骨髓瘤细胞融合获得杂交瘤细胞。发明人通过对大量样本的筛选，得到了杂交瘤细胞株LT019(保藏编号为CCTCC NO:C2020208)。
本发明人惊奇地发现，杂交瘤细胞株LT019分别能够分泌产生与人TIGIT特异性结合的特异性单克隆抗体(命名为26B12)，并且该单克隆抗体能够十分有效地结合TIGIT，降低TIGIT抑制免疫细胞的作用，促进T细胞活性，逆转NK细胞耗竭，增强免疫细胞对肿瘤的杀伤作用。进一步地，本发明人创造性地制得了抗人TIGIT的人源化抗体(命名为26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4)。
本发明人还惊奇地发现，本发明的抗体26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4具有与TIGIT结合的活性，并且具有极强的亲和力；26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4可以有效地降低TIGIT的活性。本发明的抗体具有用于治疗和/或预防肿瘤(例如肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌、睾丸癌)等疾病的潜力。由此提供了下述发明：
本发明的一个方面涉及抗TIGIT抗体或其抗原结合片段，其中，
所述抗体的重链可变区包含氨基酸序列分别如SEQ ID NOs:3-5所示的HCDR1-HCDR3；并且所述抗体的轻链可变区包含氨基酸序列分别如SEQ ID NOs:8-10所示的LCDR1-LCDR3。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗体的重链可变区的氨基酸序列选自SEQ ID NO:1、SEQ ID NO:11、SEQ ID NO:13、SEQ ID NO:15和SEQ ID NO:17；并且
所述抗体的轻链可变区的氨基酸序列选自SEQ ID NO:6、SEQ ID NO:19、SEQ ID NO:21、SEQ ID NO:23和SEQ ID NO:25。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其 中，
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:1所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:6所示；
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:11所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:19所示；
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:17所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:19所示；
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:13所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:21所示；
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:13所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:23所示；
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:15所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:21所示；
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:15所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:23所示；
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:11所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:25所示；或者
所述抗体的重链可变区的氨基酸序列如SEQ ID NO:17所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:25所示。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其中，所述的抗体包括非-CDR区，且所述非-CDR区来自不是鼠类的物种，例如来自人抗体。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗体的重链恒定区为Ig gamma-1 chain C region(例如NCBI ACCESSION:P01857)或Ig gamma-4 chain C region(例如NCBI ACCESSION:P01861.1)；轻链恒定区为Ig kappa chain C region(例如NCBI ACCESSION:P01834)。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗TIGIT抗体或其抗原结合片段选自Fab、Fab'、F(ab')2、Fd、Fv、dAb、互补决定区片段、单链抗体、人源化抗体、嵌合抗体或双抗体。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其 中，所述抗体以小于4E-10或小于4E-11的K D结合TIGIT-mFc；优选地，所述K D通过Fortebio分子相互作用仪测得。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗体以小于1.5nM、小于1.2nM或小于1nM的EC 50结合TIGIT-mFc；优选地，所述EC 50通过流式细胞仪测得。
在本发明的一些实施方案中，所述的抗TIGIT抗体为单克隆抗体。
在本发明的一些实施方案中，所述的抗TIGIT抗体为人源化抗体、嵌合抗体、多特异性抗体(例如双特异性抗体)。
在本发明的一些实施方式中，所述抗原结合片段选自Fab、Fab'、F(ab') 2、Fd、Fv、dAb、Fab/c、互补决定区片段、单链抗体(例如，scFv)、人源化抗体、嵌合抗体或双特异性抗体。
在本发明的一个或多个实施方式中，所述的抗TIGIT抗体或其抗原结合片段，其中所述抗体是由杂交瘤细胞株LT019产生的抗体，所述杂交瘤细胞株LT019保藏于中国典型培养物保藏中心(CCTCC)，保藏编号为CCTCC NO:C2020208。
本发明的另一方面涉及分离的核酸分子，其编码本发明中任一项所述的抗TIGIT抗体或其抗原结合片段。
本发明的再一方面涉及一种载体，其包含本发明的分离的核酸分子。
本发明的再一方面涉及一种宿主细胞，其包含本发明的分离的核酸分子，或者本发明的载体。
本发明的再一方面涉及杂交瘤细胞株LT019，其保藏于中国典型培养物保藏中心(CCTCC)，保藏编号为CCTCC NO:C2020208。
本发明的再一方面涉及偶联物，其包括抗体以及偶联部分，其中，所述抗体为本发明中任一项所述的抗TIGIT抗体或其抗原结合片段，所述偶联部分为可检测的标记；优选地，所述偶联部分为放射性同位素、荧光物质、发光物质、有色物质或酶。
本发明的再一方面涉及试剂盒，其包括本发明中任一项所述的抗TIGIT抗体或其抗原结合片段，或者包括本发明的偶联物；
优选地，所述试剂盒还包括第二抗体，其特异性识别所述抗体；任选地，所述第二抗体还包括可检测的标记，例如放射性同位素、荧光物质、发光物质、有色物质或 酶。
本发明的再一方面涉及本发明中任一项所述的抗体或者本发明的偶联物在制备试剂盒中的用途，所述试剂盒用于检测TIGIT在样品中的存在或其水平。
本发明的再一方面涉及一种药物组合物，其包含本发明中任一项所述的抗TIGIT抗体或其抗原结合片段或者本发明的偶联物；可选地，所述药物组合物还包括药学上可接受的载体和/或赋形剂。
在本发明的一个或多个实施方式中，所述的药物组合物，其还包含一种或多种抗PD-1抗体，或者一种或多种抗PD-L1抗体。
在本发明的一个或多个实施方式中，所述的药物组合物，其中，按照抗体的质量计算，抗TIGIT抗体或其抗原结合片段与抗PD-1抗体或抗PD-L1抗体的质量比为(1：5)-(5：1)，例如：1：5、1：4、1：3、1：2、1：1、2：1、3：1、4：1或5：1。
本发明的再一方面涉及一种双特异性抗体，其包括第一蛋白功能区和第二蛋白功能区，其中：
所述第一蛋白功能区靶向TIGIT，
所述第二蛋白功能区靶向不同于TIGIT的靶点(例如，PD-1)，
其中，所述第一蛋白功能区为本发明中任一项所述的抗体或抗原结合片段；
优选地，所述双特异性抗体为IgG-scFv模式；
优选地，所述第一蛋白功能区为本发明中任一项所述的抗体且为免疫球蛋白形式，并且所述第二蛋白功能区为单链抗体；或者
优选地，所述第一蛋白功能区为单链抗体，并且所述第二蛋白功能区为免疫球蛋白形式的抗体。
在本发明的一些实施方式中，所述的双特异性抗体，其中，本发明中任一项所述的抗体为免疫球蛋白形式。
在本发明的一些实施方式中，所述的双特异性抗体，其中，所述单链抗体为重链可变区-连接片段(linker)-轻链可变区形式。
在本发明的一些实施方式中，所述的双特异性抗体，其中，所述第一蛋白功能区和第二蛋白功能区直接连接或者通过连接片段(linker)连接；该连接片段和前面单链抗体中的连接片段可以相同或不同，均可以常用本领域常用的连接片段。
在本发明的一些实施方式中，所述的双特异性抗体，其中，所述第一蛋白功能区和第 二蛋白功能区独立地为1个、2个或者2个以上。
在本发明的一些实施方式中，所述的双特异性抗体，其中，所述单链抗体分别连接在免疫球蛋白形式的抗体的两条重链的C末端；优选地，每条重链连接一条单链抗体。
本发明的再一方面涉及一种组合产品，其包含独立包装的第一产品和第二产品，其中，
所述第一产品包含其包含本发明中任一项所述的抗TIGIT抗体或其抗原结合片段、本发明的偶联物或者本发明中任一项所述的药物组合物；
所述第二产品包含至少一种抗PD-1抗体或者至少一种抗PD-L1抗体；
优选地，所述第一产品和所述第二产品还独立地包含一种或多种药学上可接受的辅料(例如载体和/或赋形剂)；
优选地，所述组合产品还包含产品说明书。
在本发明的一个或多个实施方式中，所述的组合产品，其中，按照抗体的质量计算，抗TIGIT抗体或其抗原结合片段与抗PD-1抗体或抗PD-L1抗体的质量比为(1：5)-(5：1)，例如：1：5、1：4、1：3、1：2、1：1、2：1、3：1、4：1或5：1。
本发明的再一方面涉及本发明中任一项所述的抗体或其抗原结合片段、本发明的偶联物、本发明中任一项所述的双特异性抗体、本发明中任一项所述的药物组合物或者本发明中任一项所述的组合产品在制备治疗和/或预防肿瘤的药物中的用途；优选地，所述肿瘤选自肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌和睾丸癌中的一种或多种。
根据本发明中任一项所述的抗体或其抗原结合片段、本发明的偶联物、本发明中任一项所述的双特异性抗体、本发明中任一项所述的药物组合物或者本发明中任一项所述的组合产品，其用于治疗和/或预防肿瘤；优选地，所述肿瘤选自肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌和睾丸癌中的一种或多种。
本发明的再一方面涉及一种治疗和/或预防肿瘤的方法，包括给予有需求的受试者以有效量的本发明中任一项所述的抗体或其抗原结合片段、本发明的偶联物、本发明中任一项所述的双特异性抗体、本发明中任一项所述的药物组合物或者本发明中任一项所述的组合产品的步骤；优选地，所述肿瘤选自肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌和睾丸癌中的一种或多种。
在本发明的一些实施方式中，所述肝癌是肝细胞癌。
轻链和重链的可变区决定抗原的结合；每条链的可变区均含有三个高变区，称互补决定区(CDR)(重链(H)的CDR包含HCDR1、HCDR2、HCDR3，轻链(L)的CDR包含LCDR1、LCDR2、LCDR3；其由Kabat等人命名，见Bethesda M.d.,Sequences of Proteins of Immunological Interest,Fifth Edition,NIH Publication 1991；1-3:91-3242。
优选地，CDR也可以由IMGT编号系统定义，请参见Ehrenmann,Francois,Quentin Kaas,and Marie-Paule Lefranc.IMGT/3Dstructure-DB and IMGT/DomainGapAlign:a database and a tool for immunoglobulins or antibodies,T cell receptors,MHC,IgSF and MhcSF.Nucleic acids research 2009；38(suppl_1):D301-D307。
通过本领域技术人员所熟知的技术手段，例如通过VBASE2数据库根据IMGT定义分析单克隆抗体序列的CDR区的氨基酸序列。
本发明的涉及的抗体26B12、26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4具有相同的CDR：
其重链可变区的3个CDR区的氨基酸序列如下：
HCDR1:GHSFTSDYA(SEQ ID NO:3)
HCDR2:ISYSDST(SEQ ID NO:4)
HCDR3:ARLDYGNYGGAMDY(SEQ ID NO:5)；
其轻链可变区的3个CDR区的氨基酸序列如下：
LCDR1：QHVSTA(SEQ ID NO:8)
LCDR2：SAS(SEQ ID NO:9)
LCDR3：QQHYITPWT(SEQ ID NO:10)。
在本发明中，除非另有说明，否则本文中使用的科学和技术名词具有本领域技术人员所通常理解的含义。并且，本文中所用的细胞培养、分子遗传学、核酸化学、免疫学实验室操作步骤均为相应领域内广泛使用的常规步骤。同时，为了更好地理解本发明，下面提供相关术语的定义和解释。
如本文中所使用的，当提及TIGIT(NCBI GenBank ID:NP_776160.2)的氨基酸序列时，其包括TIGIT蛋白的全长，或者细胞外免疫球蛋白可变区(IgV)结构域或者包含细胞外免疫球蛋白可变区(IgV)结构域的片段；还包括TIGIT的融合蛋白，例如与小鼠或人IgG的Fc蛋白片段(mFc或hFc)进行融合的片段。然而，本领域技术人员理解，在TIGIT蛋白的氨基酸序列中，可天然产生或人工引入突变或变异(包括但不限于置换，缺失和/或添加)，而不影响其生物学功能。因此，在本发明中，术语“TIGIT蛋白”或“TIGIT”应包括所有此类序列，包括所示的序列以及其天然或人工的变体。并且，当描述TIGIT蛋白的序列片段时，其不仅包括的序列片段，还包括其天然或人工变体中的相应序列片段。
如本文中所使用的，术语EC 50是指半最大效应浓度(concentration for 50％of maximal effect)，是指能引起50％最大效应的浓度。
如本文中所使用的，术语“抗体”是指通常由两对多肽链(每对具有一条“轻”(L)链和一条“重”(H)链)组成的免疫球蛋白分子。抗体轻链可分类为κ和λ轻链。重链可分类为μ、δ、γ、α或ε，并且分别将抗体的同种型定义为IgM、IgD、IgG、IgA和IgE。在轻链和重链内，可变区和恒定区通过大约12或更多个氨基酸的“J”区连接，重链还包含大约3个或更多个氨基酸的“D”区。各重链由重链可变区(V H)和重链恒定区(C H)组成。重链恒定区由3个结构域(C H1、C H2和C H3)组成。各轻链由轻链可变区(V L)和轻链恒定区(C L)组成。轻链恒定区由一个结构域C L组成。抗体的恒定区可介导免疫球蛋白与宿主组织或因子，包括免疫系统的各种细胞(例如，效应细胞)和经典补体系统的第一组分(C1q)的结合。V H和V L区还可被细分为具有高变性的区域(称为互补决定区(CDR))，其间散布有较保守的称为构架区(FR)的区域。各V H和V L由按下列顺序：FR1、CDR1、FR2、CDR2、FR3、CDR3、FR4从氨基末端至羧基末端排列的3个CDR和4个FR组成。各重链/轻链对的可变区(V H和V L)分别形成抗原结合部位。氨基酸至各区域或结构域的分配遵循Kabat Sequences of Proteins of  Immunological Interest(National Institutes of Health,Bethesda M.d.(1987and 1991))，或Chothia&Lesk J.Mol.Biol.1987；196:901-917；Chothia等人Nature 1989；342:878-883或者IMGT编号系统定义，见Ehrenmann,Francois,Quentin Kaas,and Marie-Paule Lefranc."IMGT/3Dstructure-DB and IMGT/DomainGapAlign:a database and a tool for immunoglobulins or antibodies,T cell receptors,MHC,IgSF and MhcSF."Nucleic acids research 2009；38(suppl_1):D301-D307.的定义。术语“抗体”不受任何特定的产生抗体的方法限制。例如，其包括，特别地，重组抗体、单克隆抗体和多克隆抗体。抗体可以是不同同种型的抗体，例如，IgG(例如，IgG1，IgG2，IgG3或IgG4亚型)，IgA1，IgA2，IgD，IgE或IgM抗体。
如本文中所使用的，术语抗体的“抗原结合片段”是指包含全长抗体的片段的多肽，其保持特异性结合全长抗体所结合的相同抗原的能力，和/或与全长抗体竞争对抗原的特异性结合，其也被称为“抗原结合部分”。通常参见，Fundamental Immunology,Ch.7(Paul,W.,ed.,第2版，Raven Press,N.Y.(1989)，其以其全文通过引用合并入本文，用于所有目的。可通过重组DNA技术或通过完整抗体的酶促或化学断裂产生抗体的抗原结合片段。在一些情况下，抗原结合片段包括Fab、Fab'、F(ab') 2、Fd、Fv、dAb和互补决定区(CDR)片段、单链抗体(例如，scFv)、嵌合抗体、双抗体(diabody)和这样的多肽，其包含足以赋予多肽特异性抗原结合能力的抗体的至少一部分。
如本文中所使用的，术语“Fd片段”意指由V H和C H1结构域组成的抗体片段；术语“Fv片段”意指由抗体的单臂的V L和V H结构域组成的抗体片段；术语“dAb片段”意指由V H结构域组成的抗体片段(Ward等人,Nature 341:544-546(1989))；术语“Fab片段”意指由V L、V H、C L和C H1结构域组成的抗体片段；术语“F(ab') 2片段”意指包含通过铰链区上的二硫桥连接的两个Fab片段的抗体片段。
在一些情况下，抗体的抗原结合片段是单链抗体(例如，scFv)，其中V L和V H结构域通过使其能够产生为单个多肽链的连接体配对形成单价分子(参见，例如,Bird等人,Science 242:423-426(1988)和Huston等人,Proc.Natl.Acad.Sci.USA85:5879-5883(1988))。此类scFv分子可具有一般结构：NH 2-V L-接头-V H-COOH或NH 2-V H-接头-V L-COOH。合适的现有技术接头由重复的GGGGS氨基酸序列或其变体组成。例如，可使用具有氨基酸序列(GGGGS) 4的接头，但也可使用其变体(Holliger等人(1993)，Proc.Natl.Acad.Sci.USA 90:6444-6448)。可用于本发明的其他接头由Alfthan等人(1995)，Protein Eng.8:725-731，Choi等人(2001)，Eur.J.Immunol.31: 94-106，Hu等人(1996)，Cancer Res.56:3055-3061，Kipriyanov等人(1999)，J.Mol.Biol.293:41-56和Roovers等人(2001)，Cancer Immunol.描述。
在一些情况下，抗体的抗原结合片段是双抗体，即，双价抗体，其中V H和V L结构域在单个多肽链上表达，但使用太短的连接体以致不允许在相同链的两个结构域之间配对，从而迫使结构域与另一条链的互补结构域配对并且产生两个抗原结合部位(参见，例如,Holliger P.等人,Proc.Natl.Acad.Sci.USA 90:6444-6448(1993)，和Poljak R.J.等人,Structure 2:1121-1123(1994))。
在另一些情况下，抗体的抗原结合片段是“双特异性抗体”，指由第一抗体(片段)和第二抗体(片段)或抗体类似物通过偶联臂所形成的偶联物，偶联的方式包括但不限于化学反应、基因融合和酶促。抗体的抗原结合片段可以是“多特异性抗体”包括例如：三特异性抗体和四特异性抗体，前者是具有三种不同抗原结合特异性的抗体，而后者是具有四种不同抗原结合特异性的抗体。例如，经设计的锚蛋白重复蛋白(DARPin)，与IgG抗体，scFv-Fc抗体片段相连或其组合，如CN104341529A。抗IL-17a的fynomer与抗IL-6R抗体结合，如WO2015141862A1。
可使用本领域技术人员已知的常规技术(例如，重组DNA技术或酶促或化学断裂法)从给定的抗体(例如本发明提供的单克隆抗体26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4)获得抗体的抗原结合片段(例如，上述抗体片段)，并且以与用于完整抗体的方式相同的方式就特异性筛选抗体的抗原结合片段。
如本文中所使用的，术语“单抗”和“单克隆抗体”是指，来自一群高度同源的抗体分子中的一个抗体或抗体的一个片段，也即除可能自发出现的自然突变外，一群完全相同的抗体分子。单抗对抗原上的单一表位具有高特异性。多克隆抗体是相对于单克隆抗体而言的，其通常包含至少2种或更多种的不同抗体，这些不同的抗体通常识别抗原上的不同表位。单克隆抗体通常可采用Kohler等首次报道的杂交瘤技术获得(
Figure PCTCN2021126277-appb-000001
G,Milstein C.Continuous cultures of fused cells secreting antibody of predefined specificity[J].nature,1975；256(5517):495)，但也可采用重组DNA技术获得(如参见U.S.Patent 4,816,567)。
如本文中所使用的，术语“人源化抗体”是指，人源免疫球蛋白(受体抗体)的全部或部分CDR区被一非人源抗体(供体抗体)的CDR区替换后得到的抗体或抗体片段，其中的供体抗体可以是具有预期特异性、亲和性或反应性的非人源(例如，小鼠、 大鼠或兔)抗体。此外，受体抗体的构架区(FR)的一些氨基酸残基也可被相应的非人源抗体的氨基酸残基替换，或被其他抗体的氨基酸残基替换，以进一步完善或优化抗体的性能。关于人源化抗体的更多详细内容，可参见例如，Jones et al.,Nature 1986；321:522-525；Reichmann et al.,Nature 1988；332:323-329；Presta,Curr.Op.Struct.Biol.,1992；2:593-596；和Clark M.Antibody humanization:a case of the‘Emperor’s new clothes’？[J].Immunol.Today,2000；21(8):397-402。
如本文中所使用的，术语“分离的”或“被分离的”指的是，从天然状态下经人工手段获得的。如果自然界中出现某一种“分离”的物质或成分，那么可能是其所处的天然环境发生了改变，或从天然环境下分离出该物质，或二者情况均有发生。例如，某一活体动物体内天然存在某种未被分离的多聚核苷酸或多肽，而从这种天然状态下分离出来的高纯度的相同的多聚核苷酸或多肽即称之为分离的。术语“分离的”或“被分离的”不排除混有人工或合成的物质，也不排除存在不影响物质活性的其它不纯物质。
如本文中所使用的，术语“载体(vector)”是指，可将多聚核苷酸插入其中的一种核酸运载工具。当载体能使插入的多核苷酸编码的蛋白获得表达时，载体称为表达载体。载体可以通过转化，转导或者转染导入宿主细胞，使其携带的遗传物质元件在宿主细胞中获得表达。载体是本领域技术人员公知的，包括但不限于：质粒；噬菌粒；柯斯质粒；人工染色体，例如酵母人工染色体(YAC)、细菌人工染色体(BAC)或P1来源的人工染色体(PAC)；噬菌体如λ噬菌体或M13噬菌体及动物病毒等。可用作载体的动物病毒包括但不限于，逆转录酶病毒(包括慢病毒)、腺病毒、腺相关病毒、疱疹病毒(如单纯疱疹病毒)、痘病毒、杆状病毒、乳头瘤病毒、乳头多瘤空泡病毒(如SV40)。一种载体可以含有多种控制表达的元件，包括但不限于，启动子序列、转录起始序列、增强子序列、选择元件及报告基因。另外，载体还可含有复制起始位点。
如本文中所使用的，术语“宿主细胞”是指，可用于导入载体的细胞，其包括但不限于，如大肠杆菌或枯草杆菌等的原核细胞，如酵母细胞或曲霉菌等的真菌细胞，如S2果蝇细胞或Sf9等的昆虫细胞，或者如纤维原细胞，CHO细胞，COS细胞，NSO细胞，HeLa细胞，GS细胞，BHK细胞，HEK 293细胞或人细胞等的动物细胞。
如本文中使用的，术语“特异性结合”是指，两分子间的非随机的结合反应，如抗体和其所针对的抗原之间的反应。在某些实施方式中，特异性结合某抗原的抗体(或对某抗原具有特异性的抗体)是指，抗体以小于大约10 -5M，例如小于大约10 -6M、 10 -7M、10 -8M、10 -9M或10 -10M或更小的亲和力(K D)结合该抗原。
如本文中所使用的，术语“K D”是指特定抗体-抗原相互作用的解离平衡常数，其用于描述抗体与抗原之间的结合亲和力。平衡解离常数越小，抗体-抗原结合越紧密，抗体与抗原之间的亲和力越高。通常，抗体以小于大约10 -5M，例如小于大约10 -6M、10 -7M、10 -8M、10 -9M或10 -10M或更小的解离平衡常数(K D)结合抗原(例如，TIGIT蛋白)。可以使用本领域技术人员知悉的方法测定K D，例如使用Fortebio分子相互作用仪测定。
如本文中所使用的，术语“单克隆抗体”和“单抗”具有相同的含义且可互换使用；术语“多克隆抗体”和“多抗”具有相同的含义且可互换使用；术语“多肽”和“蛋白质”具有相同的含义且可互换使用。并且在本发明中，氨基酸通常用本领域公知的单字母和三字母缩写来表示。例如，丙氨酸可用A或Ala表示。
如本文中所使用的，术语“药学上可接受的载体和/或赋形剂”是指在药理学和/或生理学上与受试者和活性成分相容的载体和/或赋形剂，其是本领域公知的(参见例如Remington's Pharmaceutical Sciences.Edited by Gennaro AR,19th ed.Pennsylvania:Mack Publishing Company,1995)，并且包括但不限于：pH调节剂，表面活性剂，佐剂，离子强度增强剂。例如，pH调节剂包括但不限于磷酸盐缓冲液；表面活性剂包括但不限于阳离子，阴离子或者非离子型表面活性剂，例如Tween-80；离子强度增强剂包括但不限于氯化钠。
如本文中所使用的，术语“有效量”是指足以获得或至少部分获得期望的效果的量。例如，预防疾病(例如肿瘤)有效量是指，足以预防，阻止，或延迟疾病(例如肿瘤)的发生的量；治疗疾病有效量是指，足以治愈或至少部分阻止已患有疾病的患者的疾病和其并发症的量。
如本文中所使用的，当提及TIGIT蛋白(NCBI GenBank:NP_776160.2)的氨基酸序列时，其包括TIGIT蛋白的全长，或者TIGIT的胞外片段TIGIT ECD或者包含TIGIT ECD的片段；还包括TIGIT蛋白的全长的融合蛋白或TIGIT ECD的融合蛋白，例如与小鼠或人IgG的Fc蛋白片段(mFc或hFc)进行融合的片段。然而，本领域技术人员理解，在TIGIT蛋白的氨基酸序列中，可天然产生或人工引入突变或变异(包括但不限于置换，缺失和/或添加)，而不影响其生物学功能。因此，在本发明中，术语“添加)，蛋白”应包括所有此类序列，包括其天然或人工的变体。并且，当描述TIGIT蛋白的序列片段时，其还包括其天然或人工变体中的相应序列片段。
如本文中所使用的，术语“杂交瘤”和“杂交瘤细胞株”可互换使用，并且当提及术语“杂交瘤”和“杂交瘤细胞株”时，其还包括杂交瘤的亚克隆和后代细胞。
在本发明中，如果没有特别说明，所述“第一”(例如第一产品)和“第二”(例如第二产品)是为了指代上的区分或表述上的清楚，并不具有典型的次序上的含义。
发明的有益效果
本发明的单克隆抗体能够很好地特异性与TIGIT结合，并且具有极强的亲和力，降低TIGIT抑制免疫细胞的作用，促进T细胞活性，逆转NK细胞耗竭，增强免疫细胞对肿瘤的杀伤作用。可用于制备抑制TIGIT的药物、制备治疗或预防肿瘤(例如肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌、睾丸癌)等疾病的药物，具有良好的应用前景和市场价值。
附图说明
图1：26B12H1L1、26B12H2L2、26B12H2L3和26B12H3L2抗体与TIGIT-mFc的结合活性检测结果。
图2：26B12H3L3、26B12H1L4、26B12H4L1和26B12H4L4抗体与TIGIT-mFc的结合活性检测结果。
图3：26B12H1L1、26B12H2L2、26B12H2L3和26B12H3L2抗体与人CD155-hFc-Biotin竞争结合TIGIT-mFc的活性检测结果。
图4：26B12H3L3、26B12H1L4、26B12H4L1和26B12H4L4抗体与人CD155-hFc-Biotin竞争结合TIGIT-mFc的活性检测结果。
图5：26B12H3L3与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图6：26B12H1L1与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图7：26B12H2L2与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图8：26B12H2L3与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对 曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图9：26B12H3L2与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图10：26B12H4L4与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图11：26B12H1L4与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图12：26B12H4L1与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图13：RG6058与TIGIT-mFc亲和力常数检测结果图。图中从上到下的每对曲线中加入抗体的浓度分别为5nM、1.67nM、0.557nM、0.185nM、0.06nM。
图14：FACS检测人源化抗体26B12H2L2和RG6058与293T-TIGIT细胞膜表面抗原TIGIT结合活性。
图15：FACS检测人源化抗体26B12H2L2和RG6058与CD155竞争结合293T-TIGIT细胞膜表面TIGIT的活性。
图16：FACS检测人源化抗体26B12H2L2和RG6058与CD112竞争结合293T-TIGIT细胞膜表面TIGIT的活性。
图17：检测在Jurkat-TIGIT和HT1080-aCD3scFv细胞体系中加入TIGIT抗体后分泌IL-2的量。
图18：hTIGIT-BALB/c转基因小鼠CT26肿瘤模型效果。
图19：hTIGIT-BALB/c转基因小鼠CT26肿瘤模型体重变化。
涉及保藏的生物材料：
杂交瘤细胞株LT019，其于2020年10月23日保藏于中国典型培养物保藏中心(CCTCC)，保藏编号为CCTCC NO:C2020208，保藏地址为中国.武汉.武汉大学，邮编：430072。
本发明涉及如下的序列1-26：
1. 26B12VH的氨基酸序列
Figure PCTCN2021126277-appb-000002
Figure PCTCN2021126277-appb-000003
2. 26B12VH的核酸序列
Figure PCTCN2021126277-appb-000004
3. HCDR1:GHSFTSDYA(SEQ ID NO:3)
4. HCDR2:ISYSDST(SEQ ID NO:4)
5. HCDR3:ARLDYGNYGGAMDY(SEQ ID NO:5)
6. 26B12VL的氨基酸序列
Figure PCTCN2021126277-appb-000005
7. 26B12VL的核酸序列
Figure PCTCN2021126277-appb-000006
Figure PCTCN2021126277-appb-000007
8. LCDR1:QHVSTA(SEQ ID NO:8)
9. LCDR2:SAS(SEQ ID NO:9)
10. LCDR3:QQHYITPWT(SEQ ID NO:10)
11. 26B12H1的氨基酸序列
Figure PCTCN2021126277-appb-000008
12. 26B12H1的核酸序列
Figure PCTCN2021126277-appb-000009
13. 26B12H2的氨基酸序列
Figure PCTCN2021126277-appb-000010
14. 26B12H2的核酸序列
Figure PCTCN2021126277-appb-000011
15. 26B12H3的氨基酸序列
Figure PCTCN2021126277-appb-000012
16. 26B12H3的核酸序列
Figure PCTCN2021126277-appb-000013
17. 26B12H4的氨基酸序列
Figure PCTCN2021126277-appb-000014
18. 26B12H4的核酸序列
Figure PCTCN2021126277-appb-000015
19. 26B12L1的氨基酸序列
Figure PCTCN2021126277-appb-000016
20. 26B12L1的核酸序列
Figure PCTCN2021126277-appb-000017
21. 26B12L2的氨基酸序列
Figure PCTCN2021126277-appb-000018
22. 26B12L2的核酸序列
Figure PCTCN2021126277-appb-000019
Figure PCTCN2021126277-appb-000020
23. 26B12L3的氨基酸序列
Figure PCTCN2021126277-appb-000021
24. 26B12L3的核酸序列
Figure PCTCN2021126277-appb-000022
25. 26B12L4的氨基酸序列
Figure PCTCN2021126277-appb-000023
26. 26B12L4的核酸序列
Figure PCTCN2021126277-appb-000024
Figure PCTCN2021126277-appb-000025
具体实施方式
下面将结合实施例对本发明的实施方案进行详细描述。本领域技术人员将会理解，下面的实施例仅用于说明本发明，而不应视为限定本发明的范围。实施例中未注明具体技术或条件者，按照本领域内的文献所描述的技术或条件(例如参考J.萨姆布鲁克等著，黄培堂等译的《分子克隆实验指南》，第三版，科学出版社)或按照产品说明书进行。所用试剂或仪器未注明生产厂商者，为可以通过市场购买获得的常规产品。例如293T可以购自ATCC。
在本发明的下述实施例中，使用的BALB/c小鼠购自广东省医学实验动物中心。
在本发明的下述实施例中，所用的阳性对照抗体RG6058，其序列可参照中国公开专利CN108290946A中的序列34和序列36。
在本发明的下述实施例中，所用的293T-TIGIT细胞系由中山康方生物医药有限公司构建。293T-TIGIT细胞系由HEK293T细胞经病毒转染制得，病毒制备使用的是3rd Generation Lentiviral Systems，参见，例如A Third Generation Lentivirus Vector with a Conditional Packaging System.Dull T,Zufferey R,Kelly M,Mandel RJ,Nguyen M,Trono D,and Naldini L.J Virol.1998.72(11):8463-8471.其中所使用的慢病毒表达载体为pCDH-CMV-PD-1FL-Puro(其中TIGIT，Genebank ID:NP_776160.2；载体pCDH-CMV-Puro，购自优宝生物，产品编号：VT1480)。
实施例1：抗TIGIT抗体26B12的制备
1.杂交瘤细胞株LT019的制备
制备抗TIGIT抗体所用的抗原为人TIGIT-mFc(TIGIT为GenbankID:NP_776160.2)。取免疫后的小鼠的脾细胞与小鼠骨髓瘤细胞融合，制成杂交瘤细胞。以人TIGIT-mFc作为抗原，对杂交瘤细胞进行间接ELISA法筛选，获得能够分泌与 TIGIT特异性结合的抗体的杂交瘤细胞。对筛选得到的杂交瘤细胞，经过有限稀释法得到稳定的杂交瘤细胞株。将以上杂交瘤细胞株分别命名为杂交瘤细胞株LT019，其分泌的单克隆抗体分别命名为26B12。
杂交瘤细胞株LT019，其于2020年10月23日保藏于中国典型培养物保藏中心(CCTCC)，保藏编号为CCTCC NO:C2020208，保藏地址为中国.武汉.武汉大学，邮编：430072。
2.抗TIGIT抗体26B12的制备
用CD培养基(Chemical Defined Medium，含1％青链霉素)对上面制得的LT019细胞株在5％CO 2，37℃条件下进行培养。7天后收集细胞培养上清，通过高速离心、微孔滤膜抽真空过滤，并使用HiTrap protein A HP柱进行纯化，制得抗体26B12。
实施例2：抗TIGIT的抗体26B12的序列分析
按照培养细胞细菌总RNA提取试剂盒(Tiangen，货号DP430)的方法，从实施例1中培养的LT019细胞株中提取mRNA。
按照Invitrogen
Figure PCTCN2021126277-appb-000026
III First-Strand Synthesis System for RT-PCR试剂盒说明书合成cDNA，并进行PCR扩增。
PCR扩增产物直接进行TA克隆，具体操作参考pEASY-T1 Cloning Kit(Transgen CT101)试剂盒说明书进行。
将TA克隆的产物直接进行测序，测序结果如下：
重链可变区的核酸序列如SEQ ID NO:2所示，片段长363bp。
其编码的氨基酸序列为SEQ ID NO:1所示，长度为121个氨基酸。
其中重链HCDR1的序列如SEQ ID NO:3所示，HCDR2的序列如SEQ ID NO:4所示，HCDR3的序列如SEQ ID NO:5所示。
轻链可变区的核酸序列如SEQ ID NO:7所示，长度为321bp。
其编码的氨基酸序列为SEQ ID NO:6所示，长度为107个氨基酸。
其中轻链LCDR1的序列如SEQ ID NO:8所示，LCDR2的序列如SEQ ID NO:9所示，LCDR3的序列如SEQ ID NO:10所示。
实施例3：抗人TIGIT的人源化抗体的轻链和重链设计和制备
1.抗人TIGIT的人源化抗体26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、 26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4的轻链和重链设计
根据人TIGIT蛋白的三维晶体结构以及实施例2获得的抗体26B12的序列，通过计算机模拟抗体模型，随后根据模型设计突变，得到抗体26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4的可变区序列(抗体恒定区序列，来自NCBI的数据库，重链恒定区均采用Ig gamma-1 chain C region，ACCESSION:P01857；轻链恒定区为Ig kappa chain C region，ACCESSION:P01834)。
设计的可变区序列如下面的表A所示。
Figure PCTCN2021126277-appb-000027
以上的8个抗体26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4，重链可变区的核酸序列的长度均为363bp，其编码的氨基酸序列的长度均为121aa；轻链可变区的核酸序列的长度均为321bp，其编码的氨基酸序列的长度均为107aa。
并且上述8个抗体具有相同的HCDR1-HCDR3和LCDR1-LCDR3，如下：
HCDR1的序列如SEQ ID NO:3所示，HCDR2的序列如SEQ ID NO:4所示，HCDR3的序列如SEQ ID NO:5所示；
LCDR1的序列如SEQ ID NO:8所示，LCDR2的序列如SEQ ID NO:9所示，LCDR3的序列如SEQ ID NO:10所示。
2.人源化抗体26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4的制备
重链恒定区均采用Ig gamma-1 chain C region，ACCESSION:P01857；轻链恒定 区均采用Ig kappa chain C region，ACCESSION:P01834。
将26B12H1L1重链cDNA和轻链的cDNA、26B12H4L1重链cDNA和轻链的cDNA、26B12H2L2重链cDNA和轻链的cDNA、26B12H3L2重链cDNA和轻链的cDNA、26B12H2L3重链cDNA和轻链的cDNA、26B12H3L3重链cDNA和轻链的cDNA、26B12H1L4重链cDNA和轻链的cDNA、26B12H2L4重链cDNA和轻链的cDNA以及26B12H4L4重链cDNA和轻链的cDNA，分别克隆到pUC57simple(金斯瑞公司提供)载体中，分别获得pUC57simple-26B12H1、pUC57simple-26B12L1；pUC57simple-26B12H4、pUC57simple-26B12L1；pUC57simple-26B12H2、pUC57simple-26B12L2；pUC57simple-26B12H3、pUC57simple-26B12L2；pUC57simple-26B12H2、pUC57simple-26B12L3；pUC57simple-26B12H3、pUC57simple-26B12L3；pUC57simple-26B12H1、pUC57simple-26B12L4；pUC57simple-26B12H2、pUC57simple-26B12L4；和pUC57simple-26B12H4、pUC57simple-26B12L4。参照《分子克隆实验指南(第二版)》介绍的标准技术，EcoRI&HindIII酶切合成的重、轻链全长基因，通过限制酶(EcoRI&HindIII)的酶切亚克隆到表达载体pcDNA3.1中获得表达质粒pcDNA3.1-26B12H1、pcDNA3.1-26B12L1、pcDNA3.1-26B12H4、pcDNA3.1-126B12H2、pcDNA3.1-26B12L2、pcDNA3.1-26B12H3、pcDNA3.1-26B12L3和pcDNA3.1-26B12L4，并进一步对重组表达质粒的重/轻链基因进行测序分析。随后将含有相应的轻、重链重组质粒设计基因组合(pcDNA3.1-26B12H1/pcDNA3.1-26B12L1、pcDNA3.1-26B12H4/pcDNA3.1-26B12L1、pcDNA3.1-26B12H2/pcDNA3.1-26B12L2、pcDNA3.1-26B12H3/pcDNA3.1-26B12L2、pcDNA3.1-26B12H2/pcDNA3.1-26B12L3、pcDNA3.1-26B12H3/pcDNA3.1-26B12L3、pcDNA3.1-26B12H1/pcDNA3.1-26B12L4和pcDNA3.1-26B12H4/pcDNA3.1-26B12L4)分别共转染293F细胞后收集培养液进行纯化。测序验证正确后，制备去内毒素级别的表达质粒并将质粒瞬时转染HEK293细胞进行抗体表达，培养7天后收集细胞培养液，采用Protein A柱进行亲和纯化获得人源化抗体。
实施例4：ELISA方法测定抗体与抗原TIGIT-mFc的结合活性
实验步骤：将羊抗鼠IgG Fc，2μg/mL包被酶标板后，4℃孵育16小时。孵育结束后使用PBST洗包被了羊抗鼠IgG Fc的酶标板1次，后使用1％BSA的PBST溶 液作为酶标板封闭液，封闭2小时。酶标板结束封闭后用PBST洗板3次。再加入抗原人TIGIT-mFc 1μg/mL，置于37℃条件下孵育30分钟后用PBST洗板3次。在酶标板孔内加入PBST溶液梯度稀释的抗体，抗体稀释梯度详见表1和表2。将加入了待测抗体的酶标板置于37℃条件下孵育30分钟，孵育完成后用PBST洗板3次。洗板后加入1:5000比例稀释的HRP标记的羊抗人IgG Fc二抗工作液，置于37℃条件下孵育30分钟。孵育完成后使用PBST洗板4次，后加入TMB(Neogen，308177)避光显色4min，加入终止液终止显色反应。立即把酶标板放入酶标仪中，选择450nm光波长读取酶标板各孔的OD数值。用SoftMax Pro 6.2.1软件对数据进行分析处理。
抗体与抗原TIGIT-mFc结合的结果如图1、图2所示。各剂量的OD值见表1和表2。以抗体浓度为横坐标，吸光度值为纵坐标进行曲线拟合，计算抗体与抗原的结合EC 50，结果如表1、表2和图1、图2所示。
表1：26B12H1L1、26B12H2L2、26B12H2L3、26B12H3L2和RG6058与TIGIT-mFc的结合活性检测结果
Figure PCTCN2021126277-appb-000028
表2：26B12H3L3、26B12H1L4、26B12H4L1、26B12H4L4和RG6058与TIGIT-mFc的结合活性检测结果
Figure PCTCN2021126277-appb-000029
Figure PCTCN2021126277-appb-000030
结果显示，抗体26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4均能有效地与人TIGIT-mFc结合，结合效率呈剂量依赖关系，结合活性与同靶点阳性药RG6058相当，表明26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4具有有效结合TIGIT的功能。
实施例5:竞争ELISA方法分别测定抗体与CD155-hFc-Biotin竞争结合 TIGIT-mFc的活性
实验步骤：将TIGIT-mFc，2μg/mL包被酶标板后，4℃孵育过夜。孵育结束后使用PBST漂洗包被了抗原的酶标板1次，后使用1％BSA的PBST溶液作为酶标板封闭液，封闭2小时。酶标板结束封闭后用PBST洗板3次。在酶标板内加入PBST溶液梯度稀释的抗体，抗体浓度详见表3和表4，室温孵育10分钟后加入等体积的2μg/mL(终浓度为1μg/mL)的CD155-hFc-Biotin，和抗体混合均匀后将酶标板置于37℃条件下孵育30分钟，孵育完成后用PBST洗板3次。洗板后加入1:4000比例稀释的SA-HRP工作液，置于37℃条件下孵育30分钟。孵育完成后使用PBST洗板4次后加入TMB(Neogen，308177)避光显色5min，加入终止液终止显色反应。立即把酶标板放入酶标仪中，选择450nm光波长读取酶标板各孔的OD数值。用SoftMax Pro 6.2.1软件对数据进行分析处理。
抗体与CD155-hFc-Biotin竞争结合TIGIT-mFc的活性的结果见表3和表4。以抗体浓度为横坐标，吸光度值为纵坐标进行曲线拟合，计算抗体与CD155-hFc-Biotin竞争结合TIGIT-mFc的EC 50，结果如下表3和表4、图3和图4所示。
表3：26B12H1L1、26B12H2L2、26B12H2L3、26B12H3L2和RG6058与CD155-hFc-Biotin竞争结合TIGIT-mFc的活性检测结果
Figure PCTCN2021126277-appb-000031
Figure PCTCN2021126277-appb-000032
表4：26B12H3L3、26B12H1L4、26B12H4L1、26B12H4L4和RG6058与CD155-hFc-Biotin竞争结合TIGIT-mFc的活性检测结果
Figure PCTCN2021126277-appb-000033
结果表明，在相同实验条件下，26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4可分别与CD155-hFc-Biotin竞争结合抗原TIGIT-mFc，活性与同靶点阳性药RG6058相当，提示26B12H1L1、26B12H4L1、26B12H2L2、26B12H3L2、26B12H2L3、26B12H3L3、26B12H1L4和26B12H4L4具有有效的与CD155-hFc-Biotin竞争结合TIGIT-mFc的功能。
实施例6：使用Fortebio分子相互作用仪测定人源化抗体26B12H3L3、 26B12H1L1、26B12H2L2、26B12H2L3、26B12H3L2、26B12H4L4、26B12H1L4、 26B12H4L1和RG6058与抗原TIGIT-mFc结合的动力学参数
样品稀释缓冲液为PBS，0.02％Tween-20，0.1％BSA，pH7.4。将TIGIT-mFc以 3μg/mL的浓度固定于AMC传感器上，时间为50s，传感器在缓冲液中平衡60s，固定在传感器上的TIGIT-mFc与抗体结合，浓度为0.06-5nM(三倍稀释)，时间120s，蛋白在缓冲液中解离，时间300s。传感器采用10mM甘氨酸，pH＝1.7溶液再生。检测温度为37度，检测频率为0.3Hz，样品板震动速率为1000rpm。数据以1:1模型拟合分析，得到亲和力常数。
人源化抗体(作为对照抗体)与TIGIT的亲和力常数测定结果见表5，检测结果如图5至图13所示。
表5：人源化抗体与抗原TIGIT-mFc亲和力常数检测结果
Figure PCTCN2021126277-appb-000034
K D为亲和力常数；K D＝kdis/kon。
结果显示，人源化抗体26B12H3L3、26B12H1L1、26B12H2L2、26B12H2L3、26B12H3L2、26B12H4L4、26B12H1L4、26B12H4L1和RG6058与TIGIT-mFc的亲和力常数依次为9.64E-11M、1.64E-11M、8.40E-12M、4.85E-11M、5.40E-11M、3.69E-11M、4.63E-11M、8.57E-12M和3.16E-11M。
结果表明，TIGIT各抗体与TIGIT-mFc结合的亲和力强弱从强到弱依次为：26B12H2L2、26B12H4L1、26B12H1L1、RG6058、26B12H4L4、26B12H1L4、26B12H2L3、26B12H3L2、26B12H3L3。其中人源化抗体26B12H2L2、26B12H4L1、26B12H1L1的亲和力比阳性药物RG6058强，而26B12H4L4的亲和力与阳性药物RG6058亲和力相当。
实施例7：FACS检测人源化抗体26B12H2L2和RG6058与293T-TIGIT细胞膜 表面抗原TIGIT的结合活性
实验方法：
TIGIT载体plenti6.3/V5-TIGITFL-BSD(载体pLenti6.3购自Invitrogen公司)转染293T细胞，经筛选获得稳定表达TIGIT的细胞株293T-TIGIT细胞。
收集293T-TIGIT细胞(DMEM+10％FBS)，离心5min后去上清，重悬，计数及活率(P7，95.79％)，稀释细胞，透明尖底96孔板每个孔中加入30w细胞，每管加200μL 1％PBSA，离心5min，去上清。按实验设计每孔对应加入100μL抗体(终浓度为300nM，100nM，33.3nM，11.1nM，3.7nM，1.23nM，0.41nM，0.041nM，0.0041nM)，并设计空白对照及同型对照，冰上孵育60min。每管加200μL 1％PBSA，离心5min，去上清，洗两遍。每个样品加FITC羊抗人IgG抗体(用PBSA 500倍稀释)，冰上避光孵育40min；每管加入200μL PBSA，离心5min，去上清。加入200μL PBSA重悬细胞，转移到流式管中，流式细胞仪检测各浓度下细胞的平均荧光强度。
表6：FACS检测人源化抗体26B12H2L2和RG6058与293T-TIGIT细胞膜表面抗原TIGIT-的结合活性
Figure PCTCN2021126277-appb-000035
实验结果如表6和图14所示，阳性对照抗体RG6058与细胞膜表面抗原TIGIT结合的EC 50为1.257nM，而人源化抗体26B12H2L2与细胞膜表面抗原TIGIT-结合的EC 50为0.917nM。
实验结果表明，人源化抗体26B12H2L2结合细胞膜表面抗原TIGIT的能力比阳性对照抗体RG6058强。
实施例8：FACS检测人源化抗体26B12H2L2和RG6058与CD155或者CD112 竞争结合293T-TIGIT细胞膜表面抗原TIGIT的活性
实验方法：收集293T-TIGIT细胞，离心5min后去上清，重悬，计数及活率(94.95％)，稀释细胞，透明尖底96孔板每个孔中加入30w细胞，每管加200μL1％PBSA，离心5min，去上清。按实验设计每孔对应加入100μL抗体(终浓度为300nM，100nM，33.3nM，11.1nM，3.7nM，1.23nM，0.123nM，0.0123nM)，并设计空 白对照及同型对照，冰上孵育30min。每个样品加CD155(终浓度为10nM)或CD112(终浓度为30nM)，冰上避光孵育60min，再每管加200μL 1％PBSA，离心5min，去上清，洗两遍。每个样品加APC羊抗鼠IgG(最小交叉反应活性minimal x-reactivity)抗体(PBSA 300倍稀释)，冰上避光孵育40min；每管加入200μL PBSA，离心5min，去上清。加入200μL PBSA重悬细胞，转移到流式管中，流式细胞仪检测各浓度下细胞的平均荧光强度。
实验结果分别如表7和图15、以及表8和图16所示。
表7：FACS检测人源化抗体26B12H2L2和RG6058与CD155竞争结合293T-TIGIT细胞膜表面抗原TIGIT的活性
Figure PCTCN2021126277-appb-000036
表8：FACS检测人源化抗体26B12H2L2和RG6058与CD112竞争结合293T-TIGIT细胞膜表面抗原TIGIT的活性
Figure PCTCN2021126277-appb-000037
结果显示：阳性对照抗体RG6058竞争CD155结合TIGIT的EC 50为1.212nM，而人源化抗体26B12H2L2竞争CD155结合TIGIT的EC 50为1.049nM；阳性对照抗体RG6058竞争CD112结合TIGIT的EC 50为1.224nM，而人源化抗体26B12H2L2竞争CD112结合TIGIT的EC 50为1.140nM。
结果表明，人源化抗体26B12H2L2竞争CD155或者CD112结合细胞膜表面抗原TIGIT的能力比阳性对照抗体RG6058强。
实施例9：Jurkat-TIGIT和HT1080-aCD3scFv细胞体系中加入TIGIT抗体的 混合淋巴反应
实验方法:
TIGIT载体plenti6.3/V5-TIGITFL-BSD(载体pLenti6.3购自Invitrogen公司)转染Jurkat细胞，经筛选获得稳定表达TIGIT的细胞株Jurkat-TIGIT细胞；anti-CD3抗体载体pCDH-aCD3scFv-puro(载体pCDH-CMV-MCS-EF1-Puro购自优宝生物)转染HT-1080细胞，经筛选获得稳定表达anti-CD3scFv于细胞膜上的细胞株HT1080-aCD3scFv细胞。
收集对数生长期Jurkat-TIGIT和HT1080-aCD3scFv细胞，在96孔板中，Jurkat-TIGIT每孔加入5W细胞和HT1080-aCD3scFV每孔加入1W细胞。加入稀释的抗体(终浓度为10nM，50nM，250nM)并加入抗人CD28抗体(3μg/mL)，放入培养箱中培养48h；收集培养液上清，用IL-2ELISA检测试剂盒检测IL-2含量。
实验结果如图17所示。
结果显示，人源化抗体26B12H2L2和阳性对照抗体RG6058均可促进体系中IL-2的分泌，而且在各浓度下(10nM，50nM，250nM)人源化抗体26B12H2L2与RG6058促IL-2分泌水平相当。
结果表明，人源化抗体26B12H2L2与阳性对照抗体RG6058诱使细胞分泌IL-2的能力相当。
实施例10：26B12H2L2对在hTigit-BALB/c转基因小鼠接种CT26小鼠移植瘤的 治疗作用
采用在hTigit-BALB/c转基因小鼠(小鼠购自江苏集萃药康生物科技有限公司，采购的转基因小鼠，该小鼠正常的mouse TIGIT基因被human TIGIT基因替代)背部接种50万/只CT26细胞(小鼠结肠癌细胞株，购自ATCC)，实验具体步骤为5000万/ml的CT26细胞以每只接种100μl接种小鼠的方法建立小鼠肿瘤模型。实验小鼠每组8只，分组如下：
同型对照组G1，给药剂量为20mg/kg，给药方式为腹腔注射(i.p.)，每周两次；
实验组G2，给药剂量为4mg/kg，给药方式为腹腔注射(i.p.)，每周两次；
实验组G3，给药剂量为20mg/kg，给药方式为腹腔注射(i.p.)，每周两次，以及
阳性对照组G4，给药剂量为20mg/kg，给药方式为腹腔注射(i.p.)，每周两次。
具体方案如表9所示。
表9：小鼠CT26肿瘤模型的建模和抗体的给药方案
Figure PCTCN2021126277-appb-000038
实验结果如图18所示。
结果显示，与同型对照相比，26B12H2L2和RG6058在hTIGIT-BALB/c转基因小鼠CT26肿瘤模型上，肿瘤体积有显著的减少。
结果表明，26B12H2L2在hTIGIT-BALB/c转基因小鼠CT26肿瘤模型上有着很强的药效，效果与RG6058相当；26B12H2L2具有用于治疗和/或预防肿瘤特别是结肠癌的潜力。
同时，如图19所示，26B12H2L2对作为CT26肿瘤模型的hTIGIT-BALB/c转基因小鼠的体重没有影响，表明26B12H2L2抗体对小鼠没有产生毒副作用。
尽管本发明的具体实施方式已经得到详细的描述，本领域技术人员将会理解。根据已经公开的所有教导，可以对那些细节进行各种修改和替换，这些改变均在本发明的保护范围之内。本发明的全部范围由所附权利要求及其任何等同物给出。

Claims (28)

  1. 抗TIGIT抗体或其抗原结合片段，其中，
    所述抗体的重链可变区包含氨基酸序列分别如SEQ ID NOs:3-5所示的HCDR1-HCDR3；并且所述抗体的轻链可变区包含氨基酸序列分别如SEQ ID NOs:8-10所示的LCDR1-LCDR3。
  2. 根据权利要求1所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗体的重链可变区的氨基酸序列选自SEQ ID NO:1、SEQ ID NO:11、SEQ ID NO:13、SEQ ID NO:15和SEQ ID NO:17；并且
    所述抗体的轻链可变区的氨基酸序列选自SEQ ID NO:6、SEQ ID NO:19、SEQ ID NO:21、SEQ ID NO:23和SEQ ID NO:25。
  3. 根据权利要求1至2中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，其中，
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:1所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:6所示；
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:11所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:19所示；
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:17所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:19所示；
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:13所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:21所示；
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:13所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:23所示；
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:15所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:21所示；
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:15所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:23所示；
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:11所示，并且所述抗体的轻 链可变区的氨基酸序列如SEQ ID NO:25所示；或者
    所述抗体的重链可变区的氨基酸序列如SEQ ID NO:17所示，并且所述抗体的轻链可变区的氨基酸序列如SEQ ID NO:25所示。
  4. 根据权利要求1至3中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗TIGIT抗体或其抗原结合片段选自Fab、Fab'、F(ab')2、Fd、Fv、dAb、互补决定区片段、单链抗体、人源化抗体、嵌合抗体或双抗体。
  5. 根据权利要求1至4中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，其中，
    所述的抗体包括非-CDR区，且所述非-CDR区来自不是鼠类的物种，例如来自人抗体。
  6. 根据权利要求1至5中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗体的重链恒定区为Ig gamma-1 chain C region(例如NCBI ACCESSION:P01857)或Ig gamma-4 chain C region(例如NCBI ACCESSION:P01861.1)；轻链恒定区为Ig kappa chain C region(例如NCBI ACCESSION:P01834)。
  7. 根据权利要求1至6中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗体以小于4E-10或小于4E-11的K D结合TIGIT-mFc；优选地，所述K D通过Fortebio分子相互作用仪测得。
  8. 根据权利要求1至7中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，其中，所述抗体以小于1.5nM、小于1.2nM或小于1nM的EC 50结合TIGIT-mFc；优选地，所述EC 50通过流式细胞仪测得。
  9. 根据权利要求1至8中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，其中所述抗TIGIT抗体是由杂交瘤细胞株LT019产生的抗体，所述杂交瘤细胞株LT019保藏于中国典型培养物保藏中心(CCTCC)，保藏编号为CCTCC NO:C2020208。
  10. 分离的核酸分子，其编码权利要求1至9中任一权利要求所述的抗TIGIT抗体或其抗原结合片段。
  11. 一种载体，其包含权利要求10所述的分离的核酸分子。
  12. 一种宿主细胞，其包含权利要求10所述的分离的核酸分子，或者权利要求11所述的载体。
  13. 杂交瘤细胞株LT019，其保藏于中国典型培养物保藏中心(CCTCC)，保藏编号为CCTCC NO:C2020208。
  14. 偶联物，其包括抗体以及偶联部分，其中，所述抗体为权利要求1至9中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，所述偶联部分为可检测的标记；优选地，所述偶联部分为放射性同位素、荧光物质、发光物质、有色物质或酶。
  15. 试剂盒，其包括权利要求1至9中任一权利要求所述的抗TIGIT抗体或其抗原结合片段，或者包括权利要求14所述的偶联物；
    优选地，所述试剂盒还包括第二抗体，其特异性识别所述抗体；任选地，所述第二抗体还包括可检测的标记，例如放射性同位素、荧光物质、发光物质、有色物质或酶。
  16. 权利要求1至9中任一权利要求所述的抗体或者权利要求14所述的偶联物在制备试剂盒中的用途，所述试剂盒用于检测TIGIT在样品中的存在或其水平。
  17. 一种双特异性抗体，其包括第一蛋白功能区和第二蛋白功能区，其中：
    所述第一蛋白功能区靶向TIGIT，
    所述第二蛋白功能区靶向不同于TIGIT的靶点(例如，PD-1)，
    其中，所述第一蛋白功能区为权利要求1至9中任一权利要求所述的抗体或抗原结合片段；
    优选地，所述双特异性抗体为IgG-scFv模式；
    优选地，所述第一蛋白功能区为权利要求1至9中任一权利要求所述的抗体且为免疫球蛋白形式，并且所述第二蛋白功能区为单链抗体；或者
    优选地，所述第一蛋白功能区为单链抗体，并且所述第二蛋白功能区为靶向不同于TIGIT的靶点(例如，PD-1)的免疫球蛋白形式的抗体。
  18. 根据权利要求17所述的双特异性抗体，其中，所述第一蛋白功能区和第二蛋白功能区直接连接或者通过连接片段连接。
  19. 根据权利要求17至18中任一权利要求所述的双特异性抗体，其中，所述第一蛋白功能区和第二蛋白功能区独立地为1个、2个或者2个以上。
  20. 根据权利要求17至19中任一权利要求所述的双特异性抗体，其中，所述单链抗体分别连接在免疫球蛋白形式的抗体的两条重链的C末端。
  21. 一种药物组合物，其包含权利要求1至9中任一权利要求所述的抗TIGIT抗体或其抗原结合片段或者权利要求14所述的偶联物；可选地，所述药物组合物还包括药学上可接受的载体和/或赋形剂。
  22. 根据权利要求21所述的药物组合物，其还包含一种或多种抗PD-1抗体，或者一种或多种抗PD-L1抗体。
  23. 根据权利要求21或22所述的药物组合物，其中，按照抗体的质量计算，抗TIGIT抗体或其抗原结合片段与抗PD-1抗体或抗PD-L1抗体的质量比为(1:5)-(5:1)。
  24. 一种组合产品，其包含独立包装的第一产品和第二产品，其中，
    所述第一产品包含其包含权利要求1至9中任一权利要求所述的抗TIGIT抗体或其抗原结合片段、权利要求14所述的偶联物或者权利要求21至23中任一权利要求所述的药物组合物；
    所述第二产品包含至少一种抗PD-1抗体或者至少一种抗PD-L1抗体；
    优选地，所述第一产品和所述第二产品还独立地包含一种或多种药学上可接受的 辅料；
    优选地，所述组合产品还包含产品说明书。
  25. 根据权利要求24所述的组合产品，其中，按照抗体的质量计算，抗TIGIT抗体或其抗原结合片段与抗PD-1抗体或抗PD-L1抗体的质量比为(1:5)-(5:1)。
  26. 权利要求1至9中任一权利要求所述的抗体或其抗原结合片段、权利要求14所述的偶联物、权利要求17至20中任一权利要求所述的双特异性抗体或者权利要求21至23中任一权利要求所述的药物组合物在制备治疗和/或预防肿瘤的药物中的用途；
    优选地，所述肿瘤选自肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌和睾丸癌中的一种或多种。
  27. 根据权利要求1至9中任一权利要求所述的抗体或其抗原结合片段或者权利要求17至20中任一权利要求所述的双特异性抗体，其用于治疗和/或预防肿瘤；
    优选地，所述肿瘤选自肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌和睾丸癌中的一种或多种。
  28. 一种治疗和/或预防肿瘤的方法，包括给予有需求的受试者以有效量的根据权利要求1至9中任一权利要求所述的抗体或其抗原结合片段或者权利要求17至20中任一权利要求所述的双特异性抗体的步骤；
    优选地，所述肿瘤选自肝癌、肾癌、脑瘤、尿路上皮癌、骨肿瘤、胆管癌、非小细胞肺癌、小细胞肺癌、乳腺癌、卵巢癌、结直肠癌、黑色素癌、胰腺癌、宫颈瘤、多发性骨髓瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、B淋巴细胞瘤、卵巢癌、浆细胞癌、子宫内膜癌、前列腺癌和睾丸癌中的一种或多种。
PCT/CN2021/126277 2020-10-26 2021-10-26 抗tigit抗体、其药物组合物及用途 Ceased WO2022089392A1 (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
JP2023525079A JP7780521B2 (ja) 2020-10-26 2021-10-26 抗ｔｉｇｉｔ抗体、その医薬組成物及び用途
US18/250,440 US20240002504A1 (en) 2020-10-26 2021-10-26 Anti-tigit antibody, and pharmaceutical composition and use thereof
KR1020237016952A KR20230098221A (ko) 2020-10-26 2021-10-26 항-tigit 항체, 약학 조성물 및 이의 용도
EP21885119.4A EP4253414A4 (en) 2020-10-26 2021-10-26 Anti-tigit antibody, and pharmaceutical composition and use thereof
AU2021372706A AU2021372706A1 (en) 2020-10-26 2021-10-26 Anti-tigit antibody, and pharmaceutical composition and use thereof
CA3194641A CA3194641A1 (en) 2020-10-26 2021-10-26 Anti-tigit antibody, and pharmaceutical composition and use thereof
IL302411A IL302411A (en) 2020-10-26 2021-10-26 Anti-Tigit antibody, and the composition of the drugs and their use
MX2023004808A MX2023004808A (es) 2020-10-26 2021-10-26 Anticuerpo anti-tigit y composicion farmaceutica y uso del mismo.
ZA2023/05217A ZA202305217B (en) 2020-10-26 2023-05-11 Anti-tigit antibody, and pharmaceutical composition and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202011153458.2 2020-10-26
CN202011153458 2020-10-26

Publications (1)

Publication Number Publication Date
WO2022089392A1 true WO2022089392A1 (zh) 2022-05-05

Family

ID=81383552

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/126277 Ceased WO2022089392A1 (zh) 2020-10-26 2021-10-26 抗tigit抗体、其药物组合物及用途

Country Status (11)

Country Link
US (1) US20240002504A1 (zh)
EP (1) EP4253414A4 (zh)
JP (1) JP7780521B2 (zh)
KR (1) KR20230098221A (zh)
CN (1) CN114478769B (zh)
AU (1) AU2021372706A1 (zh)
CA (1) CA3194641A1 (zh)
IL (1) IL302411A (zh)
MX (1) MX2023004808A (zh)
WO (1) WO2022089392A1 (zh)
ZA (1) ZA202305217B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4375300A4 (en) * 2021-07-23 2025-08-27 Akeso Biopharma Inc PHARMACEUTICAL COMPOSITION AND ITS USE

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022330896A1 (en) * 2021-08-20 2024-02-22 Akeso Biopharma, Inc. FUSION PROTEIN CONTAINING ANTI-TIGIT ANTIBODY AND TGF-βR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
CN116284395B (zh) * 2022-12-12 2024-11-08 合肥天港免疫药物有限公司 抗cd155的抗体及其应用
JP2026508210A (ja) * 2023-02-20 2026-03-10 中山康方生物医▲藥▼有限公司 ＴＧＦ－βＲＩＩ細胞外領域断片を含む融合タンパク質、その医薬組成物、およびその使用
WO2025255297A1 (en) * 2024-06-05 2025-12-11 Agilent Technologies, Inc. Anti-human tigit antibodies for in vitro diagnostics

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN104341529A (zh) 2013-07-26 2015-02-11 三星电子株式会社 带有DARPin的双特异性嵌合蛋白
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
WO2016191643A2 (en) * 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2017053748A2 (en) * 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体
CN108883164A (zh) * 2016-03-04 2018-11-23 Jn生物科学有限责任公司 针对tigit的抗体
CN110818795A (zh) * 2020-01-10 2020-02-21 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CN110997720A (zh) * 2017-07-27 2020-04-10 Iteos治疗公司 抗tigit抗体
CN111744013A (zh) * 2019-03-29 2020-10-09 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111836831A (zh) * 2018-02-26 2020-10-27 豪夫迈·罗氏有限公司 用于抗tigit拮抗剂抗体和抗pd-l1拮抗剂抗体治疗的给药
CN109206523A (zh) * 2018-08-27 2019-01-15 沣潮医药科技（上海）有限公司 Tigit免疫粘附素、制备方法及用途
CN109384846B (zh) * 2018-09-25 2020-03-03 合肥瑞达免疫药物研究所有限公司 能够结合tigit的抗体或其抗原结合片段及用途
CN111196852A (zh) * 2018-11-16 2020-05-26 四川科伦博泰生物医药股份有限公司 抗tigit抗体及其用途
CN109734806B (zh) * 2019-03-15 2022-07-01 安徽安科生物工程（集团）股份有限公司 一种全人源抗huTIGIT单克隆抗体及其应用
CN111705066B (zh) * 2020-07-01 2022-06-07 江苏莱森生物科技研究院有限公司 一种经基因修饰的tigit蛋白及其单克隆抗体和应用
IL310217A (en) * 2021-07-23 2024-03-01 Akeso Biopharma Inc Pharmaceutical composition and use
AU2022330896A1 (en) * 2021-08-20 2024-02-22 Akeso Biopharma, Inc. FUSION PROTEIN CONTAINING ANTI-TIGIT ANTIBODY AND TGF-βR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
CN104341529A (zh) 2013-07-26 2015-02-11 三星电子株式会社 带有DARPin的双特异性嵌合蛋白
WO2015141862A1 (en) 2014-03-17 2015-09-24 Mitsubishi Tanabe Pharma Corporation Antibody-fynomer conjugates
CN107207594A (zh) * 2014-12-23 2017-09-26 百时美施贵宝公司 针对tigit的抗体
WO2016191643A2 (en) * 2015-05-28 2016-12-01 Oncomed Pharmaceuticals, Inc. Tigit-binding agents and uses thereof
WO2017053748A2 (en) * 2015-09-25 2017-03-30 Genentech, Inc. Anti-tigit antibodies and methods of use
CN108290946A (zh) 2015-09-25 2018-07-17 豪夫迈·罗氏有限公司 抗tigit抗体和使用方法
CN108883164A (zh) * 2016-03-04 2018-11-23 Jn生物科学有限责任公司 针对tigit的抗体
CN110997720A (zh) * 2017-07-27 2020-04-10 Iteos治疗公司 抗tigit抗体
CN111744013A (zh) * 2019-03-29 2020-10-09 江苏恒瑞医药股份有限公司 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN110818795A (zh) * 2020-01-10 2020-02-21 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
"GenBank", Database accession no. NP 776160.2
"Genebank", Database accession no. NP_776160.2
"Molecular Cloning: A Laboratory Manual"
"NCBI", Database accession no. P01861.1
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY
ALFTHAN, PROTEIN ENG., vol. 8, 1995, pages 725 - 731
BIRD ET AL., SCIENCE, vol. 242, 1988, pages 423 - 426
CHOI ET AL., EUR. J. IMMUNOL., vol. 31, 2001, pages 94 - 106
CHOTHIA ET AL., NATURE, vol. 341, 1989, pages 544 - 546
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 3242
CLARK M.: "Antibody humanization: a case of the 'Emperor's new clothes'? [J", IMMUNOL. TODAY, vol. 21, no. 8, 2000, pages 397 - 402, XP004215168, DOI: 10.1016/S0167-5699(00)01680-7
DOLGIN ELIE: "Antibody engineers seek optimal drug targeting TIGIT checkpoint", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP US, NEW YORK, vol. 38, no. 9, 1 September 2020 (2020-09-01), New York, pages 1007 - 1009, XP037237858, ISSN: 1087-0156, DOI: 10.1038/s41587-020-0666-1 *
DUAN XIANGGUOLIU JUANXICUI JIANJIAN ET AL.: "Expression of TIGIT/CD155 and correlations with clinical pathological features in human hepatocellular carcinoma[J", MOL MED REP, vol. 20, 2019, pages 3773 - 3781
DULL TZUFFEREY RKELLY MMANDEL RJNGUYEN MTRONO DNALDINI L.: "A Third Generation Lentivirus Vector with a Conditional Packaging System", J VIROL., vol. 72, no. 11, 1998, pages 8463 - 8471, XP055715204, DOI: 10.1128/JVI.72.11.8463-8471.1998
EHRENMANN, FRANCOISQUENTIN KAASMARIE-PAULE LEFRANC: "IMGT/3Dstructure-DB and IMGT/DomainGapAlign: a database and a tool for immunoglobulins or antibodies, T cell receptors, MHC, IgSF and MhcSF", NUCLEIC ACIDS RESEARCH, vol. 38, no. 1, 2009, pages D301 - D307
HOLLIGER P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 6444 - 6448
HU ET AL., CANCER RES., vol. 56, 1996, pages 3055 - 3061
HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 5879 - 5883
JOHNSTON R JCOMPS-AGRAR LHACKNEY J ET AL.: "The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function[J", CANCER CELL, vol. 26, no. 6, 2014, pages 923 - 937, XP029111576, DOI: 10.1016/j.ccell.2014.10.018
JONES ET AL., NATURE, vol. 321, 1986, pages 522 - 525
KIPRIYANOV ET AL., J. MOL. BIOL., vol. 293, 1999, pages 41 - 56
KOHLER GMILSTEIN C: "Continuous cultures of fused cells secreting antibody of predefined specificity [J", NATURE, vol. 256, no. 5517, 1975, pages 495, XP037052082, DOI: 10.1038/256495a0
LI X-YDAS ILEPLETIER A ET AL.: "CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms", J CLIN INVEST, vol. 128, 2018, pages 2613 - 25, XP055694771, DOI: 10.1172/JCI98769
LI, GUOHUA ET AL.: "Preparation and Activity Identification of Anti-TIGIT Monoclonal Antibody", JOURNAL OF MEDICAL MOLECULAR BIOLOGY, vol. 17, no. 1, 17 January 2020 (2020-01-17), pages 52 - 56, XP009536475, ISSN: 1672-8009 *
MA LINLIN, JUNWEI GAI, PENG QIAO, YANFEI LI, XIAOFEI LI, MIN ZHU, GUANGHUI LI, YAKUN WAN: "A novel bispecific nanobody with PD-L1 TIGIT dual immune checkpoint blockade", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 531, 8 August 2020 (2020-08-08), pages 144 - 151, XP055826617, DOI: 10.1016/j.bbrc.2020.07.072 *
MARTINET LSMYTH M J: "Balancing natural killer cell activation through paired receptors[J", NATURE REVIEWS IMMUNOLOGY, vol. 15, no. 4, 2015, pages 243 - 254, XP037923259, DOI: 10.1038/nri3799
POLJAK R. ET AL., STRUCTURE, vol. 2, 1994, pages 1121 - 1123
PRESTA, CURR. OP. STRUCT. BIOL., vol. 2, 1992, pages 593 - 596
REICHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 329
ROOVERS, CANCER IMMUNOL., 2001
See also references of EP4253414A4
STANIETSKY NSIMIC HARAPOVIC J ET AL.: "The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity[J", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 42, 2009, pages 17858 - 17863, XP055215810, DOI: 10.1073/pnas.0903474106
WHELAN SOPHIR EKOTTURI MF ET AL.: "PVRIG and PVRL2 electrode Induced in Cancer and Inhibit CD8+ T-cell function", CANCER IMMUNOL RES, vol. 7, 2019, pages 257 - 68, XP055794523, DOI: 10.1158/2326-6066.CIR-18-0442
YU XHARDEN KGONZALEZ L C ET AL.: "The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells[J", NATURE IMMUNOLOGY, vol. 10, no. 1, 2009, pages 48
ZHANG QBI JZHENG X ET AL.: "Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity[J", NATURE IMMUNOLOGY, vol. 19, no. 7, 2018, pages 723 - 732, XP036533618, DOI: 10.1038/s41590-018-0132-0
ZHONG TINGTING, PANG XINGHUA, HUANG ZHAOLIANG, CHEN NA, JIN XIAOPING, XIA YU, WANG MAXWELL ZHONGMIN, AKESO BAIYONG LI: "TWO TYPES OF ANTI-TIGIT ANTIBODIES WITH DISTINCT BINDING EPITOPE AND FUNCTIONAL ACTIVITIES", J IMMUNOTHER CANCER, vol. 8, no. 3, 9 November 2020 (2020-11-09), XP055926640, DOI: 10.1136/jitc-2020-SITC2020.0184 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4375300A4 (en) * 2021-07-23 2025-08-27 Akeso Biopharma Inc PHARMACEUTICAL COMPOSITION AND ITS USE

Also Published As

Publication number Publication date
AU2021372706A1 (en) 2023-06-08
CN114478769A (zh) 2022-05-13
CN114478769B (zh) 2023-03-28
JP7780521B2 (ja) 2025-12-04
KR20230098221A (ko) 2023-07-03
IL302411A (en) 2023-06-01
MX2023004808A (es) 2023-05-10
JP2023546508A (ja) 2023-11-02
EP4253414A4 (en) 2024-10-16
EP4253414A1 (en) 2023-10-04
CA3194641A1 (en) 2022-05-05
US20240002504A1 (en) 2024-01-04
ZA202305217B (en) 2024-09-25

Similar Documents

Publication Publication Date Title
CN106977602B (zh) 一种抗pd1单克隆抗体、其药物组合物及其用途
CN114181310B (zh) 抗tigit抗体、其药物组合物及用途
WO2018113258A1 (zh) 抗pd-1抗体及其用途
CN106632674A (zh) 一种抗pd-1单克隆抗体、其药物组合物及其用途
JP7780521B2 (ja) 抗ｔｉｇｉｔ抗体、その医薬組成物及び用途
US20240352153A1 (en) Pharmaceutical composition and use
US20250376517A1 (en) Anti-cldn18.2 antibody, and pharmaceutical composition and use thereof
WO2023186081A1 (zh) 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途
CN114106182B (zh) 抗tigit的抗体及其用途
WO2023186063A1 (zh) 抗pvrig抗体、其药物组合物及用途
WO2023088337A1 (zh) 抗tigit-抗pd-l1双特异性抗体、其药物组合物及用途
WO2023020625A1 (zh) 包含抗TIGIT抗体和TGF-βR的融合蛋白、其药物组合物及用途
US20230331862A1 (en) Antibody specifically bound to glycosylated ceacam5
CN120603856A (zh) 三特异性抗原结合分子及其应用
HK40093009A (zh) 抗tigit抗体、其药物组合物及用途
EA049283B1 (ru) Антитело к tigit и его фармацевтическая композиция и применение
HK40096798A (zh) 抗cldn18.2抗体、其药物组合物及用途
HK40129144A (zh) 抗il-1rap抗体、其药物组合物及用途
HK40089230A (zh) 药物组合物及用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21885119

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3194641

Country of ref document: CA

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112023007141

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 18250440

Country of ref document: US

Ref document number: 2023525079

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 202347030240

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20237016952

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112023007141

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20230417

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021885119

Country of ref document: EP

Effective date: 20230526

ENP Entry into the national phase

Ref document number: 2021372706

Country of ref document: AU

Date of ref document: 20211026

Kind code of ref document: A

WWG Wipo information: grant in national office

Ref document number: 202391008

Country of ref document: EA